var title_f13_33_13840="Postoperative cardiac shift CT";
var content_f13_33_13840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shift in mediastinal position following pneumonectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest CT demonstrates the postoperative change in location of mediastinal organs, with the heart abutting the chest wall. Blind chest tube or needle placement into the postpneumonectomy space may puncture the heart or great vessels.",
"    <div class=\"footnotes\">",
"     LV: left ventricle, RV: right ventricle, LA: left artium, RA: right artium, a: descending aorta, e: esophagus.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Irwin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13840=[""].join("\n");
var outline_f13_33_13840=null;
var title_f13_33_13841="Livedo reticularis - lower extremities";
var content_f13_33_13841=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Livedo reticularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A red-blue, reticulated vascular network is present on the legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13841=[""].join("\n");
var outline_f13_33_13841=null;
var title_f13_33_13842="AML FAB M2 and t8 21";
var content_f13_33_13842=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute myeloid leukemia with t(8;21)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow smear from a 23-year-old female with acute myeloid leukemia with maturation (FAB-M2) associated with a t(8;21) chromosomal aabnormality. The myeloblasts have abundant cytoplasm and cytoplasmic vacuoles (black arrows). One myeloblast contains a prominent Auer rod (red arrow). (Wright-Giemsa stain).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13842=[""].join("\n");
var outline_f13_33_13842=null;
var title_f13_33_13843="R parkeri eschar and rash";
var content_f13_33_13843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    R parkeri eschar and rash",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 269px; height: 439px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Paddock, CD, Finley, RW, Wright, CS, et al. Rickettsia parkeri Rickettsiosis and Its Clinical Distinction from Rocky Mountain Spotted Fever. Clin Infect Dis 2008; 47:1188. Copyright &copy;2008 University of Chicago Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13843=[""].join("\n");
var outline_f13_33_13843=null;
var title_f13_33_13844="Meclizine: Patient drug information";
var content_f13_33_13844=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Meclizine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"     see \"Meclizine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/62/18404?source=see_link\">",
"     see \"Meclizine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Antivert&reg;;",
"     </li>",
"     <li>",
"      Bonine&reg; [OTC] [DSC];",
"     </li>",
"     <li>",
"      Dramamine&reg; Less Drowsy Formula [OTC];",
"     </li>",
"     <li>",
"      Medi-Meclizine [OTC];",
"     </li>",
"     <li>",
"      Trav-L-Tabs&reg; [OTC];",
"     </li>",
"     <li>",
"      VertiCalm&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help motion sickness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692129",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dizziness (vertigo).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702450",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to meclizine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695815",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 hour before travel if using for motion sickness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10828 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13844=[""].join("\n");
var outline_f13_33_13844=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191757\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014644\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014643\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014648\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014649\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014651\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014646\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014647\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014652\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014653\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=related_link\">",
"      Meclizine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/62/18404?source=related_link\">",
"      Meclizine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_33_13845="Cervical cerclage procedure with dilated cervix";
var content_f13_33_13845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Cervical cerclage procedure with dilated cervix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Membranes herniating through effaced and widely dilated cervix (A). Replacement of membranes into the uterus by gentle traction on stay sutures (B). Placement of 2 rows of encircling sutures (C). Final appearance of the cervix (D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Olatunbosun, OA, Dyck, F. Cervical cerclage operation for a dilated cerfix. Obstet Gynecol 1981; 57:166. Reprinted with permission from the American College of Obstetricians and Gynecologists.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13845=[""].join("\n");
var outline_f13_33_13845=null;
var title_f13_33_13846="Nonscarring hair loss";
var content_f13_33_13846=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonscarring hair loss",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/33/13846/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13846/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13846/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/33/13846/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13846/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13846/contributors\">",
"     Maria Hordinsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/33/13846/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13846/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/33/13846/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hair loss, or alopecia, is classified broadly as either scarring or nonscarring:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scarring alopecia refers to hair loss associated with fibrosis and scar tissue that replaces and often permanently destroys the hair follicle. Examples include discoid lupus erythematosus, acne keloidalis, folliculitis decalvans, lichen planopilaris, late stage traction alopecia, and dissecting cellulitis.",
"     </li>",
"     <li>",
"      Nonscarring alopecia refers to hair loss without permanent destruction of the hair follicle. Examples include anagen effluvium, androgenetic alopecia, inherited disorders of the hair shaft, telogen effluvium, alopecia areata, and hair breakage related to external insults, such as acquired trichorrhexis nodosa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All types of hair loss can be psychologically debilitating [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13846/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, psychologic support is essential for patients with hair loss. This review discusses the major nonscarring alopecias. Information on the evaluation and diagnosis of hair loss and more detailed information on individual causes of nonscarring hair loss are available separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9690?source=see_link\">",
"     \"Evaluation and diagnosis of hair loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link\">",
"     \"Treatment of androgenetic alopecia in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31752?source=see_link\">",
"     \"Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14344?source=see_link\">",
"     \"Female pattern hair loss (androgenetic alopecia in women): Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alopecia areata\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4330?source=see_link\">",
"     \"Management of alopecia areata\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HAIR GROWTH CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In humans, all terminal hair follicles are present at birth. Growth of each of these follicles on the scalp is cyclic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13846/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The growth phase, termed",
"      <strong>",
"       anagen",
"      </strong>",
"      , lasts two to six years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The involutional phase, termed",
"      <strong>",
"       catagen",
"      </strong>",
"      , lasts two to three weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The resting phase, termed",
"      <strong>",
"       telogen",
"      </strong>",
"      , lasts two to three months. Hair is released from the hair shaft and shed at the end of telogen, and the next cycle is initiated. Telogen hairs are characterized by a mature root sheath, or \"club,\" at the proximal end (",
"      <a class=\"graphic graphic_figure graphicRef50528 \" href=\"UTD.htm?2/12/2255\">",
"       figure 1",
"      </a>",
"      ). The term",
"      <strong>",
"       exogen",
"      </strong>",
"      has been used to describe the phase of active shedding [",
"      <a class=\"abstract\" href=\"UTD.htm?13/33/13846/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the normal scalp, approximately 80 to 90 percent of follicles are growing (anagen), about 5 to 10 percent are resting (telogen), and 1 to 3 percent are undergoing involution (catagen) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13846/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Each day up to 100 hairs are shed from the scalp and about the same number of follicles enter anagen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13846/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANDROGENETIC ALOPECIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgenetic alopecia is the most common type of nonscarring hair loss (",
"    <a class=\"graphic graphic_picture graphicRef83804 graphicRef83805 graphicRef83802 \" href=\"UTD.htm?38/33/39450\">",
"     picture 1A-C",
"    </a>",
"    ). In Caucasian populations it is estimated to affect up to 80 percent of men by age 80 and up to 40 percent of women by age 70 (",
"    <a class=\"graphic graphic_picture graphicRef63010 \" href=\"UTD.htm?28/36/29253\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13846/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Androgenetic alopecia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link\">",
"     \"Treatment of androgenetic alopecia in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ALOPECIA AREATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alopecia areata is a chronic inflammatory disorder affecting hair follicles and sometimes the nails that produces nonscarring hair loss (",
"    <a class=\"graphic graphic_picture graphicRef71583 graphicRef58252 \" href=\"UTD.htm?41/9/42137\">",
"     picture 3A-B",
"    </a>",
"    ). Patients typically develop discrete areas of complete hair loss. Alopecia areata is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alopecia areata\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4330?source=see_link\">",
"     \"Management of alopecia areata\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TELOGEN EFFLUVIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telogen effluvium is the most common cause of diffuse hair loss. The disease results in reversible diffuse loss of mature, terminal hairs, usually following a significant stressful event (",
"    <a class=\"graphic graphic_picture graphicRef76636 \" href=\"UTD.htm?9/36/9792\">",
"     picture 4",
"    </a>",
"    ). Common triggers include pregnancy, severe weight loss (including with dieting), major illnesses and surgery, and traumatic psychological events.",
"   </p>",
"   <p>",
"    Normal hair loss averages 75 to 100 hairs per day. In telogen effluvium, rather than hair being lost in a staggered fashion, a stress triggers a shift of many follicles into the telogen phase, causing diffuse hair loss that peaks approximately three to four months after the inciting event. Usually up to 20 percent of the hair must be lost before it is cosmetically apparent. Thus, complaints of hair loss should not be discounted in someone who still has a full head of hair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of nonscarring hair loss requires a careful history combined with a good physical examination. Knowledge of an inciting stressful event in a patient with diffuse hair loss suggests the possibility of telogen effluvium. Patterned hair loss suggests the possibility of other disorders such as androgenetic alopecia, alopecia areata, and trichotillomania. However, clinicians should be aware that telogen effluvium may coexist with other types of hair loss.",
"   </p>",
"   <p>",
"    If still in doubt, diagnostic testing may be useful for identifying telogen effluvium. A \"pull\" test can document an active shedding process. The clinician carefully grasps about two to three dozen hairs and lightly tugs to see how many hairs come out. Obtaining more than five telogen (club) hairs is abnormal (",
"    <a class=\"graphic graphic_figure graphicRef50528 \" href=\"UTD.htm?2/12/2255\">",
"     figure 1",
"    </a>",
"    ). Unfortunately, this test has poor sensitivity and high interrater variability. The test may be negative if the hair was shampooed on the day of evaluation, as the majority of telogen hairs may have been removed from the scalp during shampooing and rinsing.",
"   </p>",
"   <p>",
"    Finally, patients can also perform daily counts of hair loss. Normally, patients may lose up to 100 hairs per day, with more hair loss noted on days of shampooing. Daily hair loss of several hundred mature, telogen hairs is usually abnormal. A history of an inciting event is helpful, but the absence of such an event does not rule out the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Anagen effluvium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anagen effluvium involves loss of growing (anagen) hair fibers. Because the majority of hair is in this phase, acute loss involves 80 to 90 percent of hair. Anagen effluvium results from alkylating, antimitotic, or cytotoxic agents (eg, cancer chemotherapy) 10 to 14 days after the insult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44232?source=see_link\">",
"     \"Chemotherapy-induced alopecia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Androgenetic alopecia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgenetic alopecia in men involves gradual, not acute, loss of hair from the vertex or frontal hairline (",
"    <a class=\"graphic graphic_picture graphicRef63010 \" href=\"UTD.htm?28/36/29253\">",
"     picture 2",
"    </a>",
"    ). In women the disease can be diffuse and difficult to distinguish clinically from telogen effluvium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of diffuse hair loss should be considered if no inciting event can be identified. Many medications can cause hair loss (",
"    <a class=\"graphic graphic_table graphicRef80170 \" href=\"UTD.htm?14/47/15099\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13846/abstract/9\">",
"     9",
"    </a>",
"    ]. Additional conditions to consider include thyroid disease, connective tissue disease, hypervitaminosis A, syphilis, and nutritional deficiencies of zinc or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    . The impact of iron deficiency on hair loss is a subject of debate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13846/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory measurements that are appropriate in a patient with diffuse hair loss of uncertain etiology include thyroid function studies, a complete blood count (CBC), and iron studies. The effect of correcting low ferritin levels on hair loss is variable.",
"   </p>",
"   <p>",
"    In patients with historical risk factors for sexually transmitted diseases, testing for syphilis with a rapid plasma reagin (RPR) is indicated. In patients with other evidence of an autoimmune disorder, testing for such disorders may include an antinuclear antibody (ANA) titer.",
"   </p>",
"   <p>",
"    In women with diffuse hair loss and evidence of androgen excess (eg, acne, hirsutism, amenorrhea), testing should include a total and free testosterone, dehydroepiandrosterone sulfate (DHEAS), and prolactin levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific treatment for telogen effluvium. The first goal of therapy is to identify the cause. Review medications that the patient is taking and consider checking thyroid function tests, a serum ferritin, and CBC in unclear cases. Consider obtaining an ANA if the patient has systemic complaints suggestive of connective tissue disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with telogen effluvium should be reassured that they will not lose all of their hair, that the process is usually reversible, and that regrowth should occur over the next three to four months.",
"     </li>",
"     <li>",
"      Styling options (eg, permanents) may help existing hair look fuller and will not cause damage.",
"     </li>",
"     <li>",
"      Volumizing shampoos (readily available in grocery stores and pharmacies) may also help existing hair look fuller.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TRAUMATIC ALOPECIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic alopecia includes alopecia caused by mechanical traction, chemical or heat-related trauma, and trichotillomania (nervous, self-induced hair pulling). Traction alopecia results from styling techniques that involve chronic tension on the hair and is characterized by reversible loss of hair that can become permanent if traction continues. The habits of pulling, twisting, and plucking hairs that characterize trichotillomania cause a bizarre distribution of broken off hairs that is initially reversible. Similar to traction alopecia, hair loss may become permanent if the behavior persists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of hair loss in traction alopecia varies depending upon styling techniques, but it is most prominent in areas where greatest tension occurs (",
"    <a class=\"graphic graphic_picture graphicRef60331 \" href=\"UTD.htm?37/36/38468\">",
"     picture 5",
"    </a>",
"    ). A bizarre, asymmetric, and irregular hair loss pattern is characteristic of trichotillomania (",
"    <a class=\"graphic graphic_picture graphicRef67336 \" href=\"UTD.htm?2/30/2535\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Damage to the hair fiber induced by chemicals or heat typically presents with irregular hair breakage, which is erroneously perceived by some patients as a failure of hair to grow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is made on the basis of the pattern of hair loss. The history should include the exact styling techniques and products used. In cases of chemical or heat-induced hair breakage, microscopic examination of the hair shaft typically reveals trichorrhexis nodosa (focal fraying of the hair cortex). Occasionally a biopsy specimen is necessary to diagnose trichotillomania if the patient denies any hair-pulling habit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Alopecia areata",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hairs are not broken off at various lengths. There should be areas of smooth hair loss in round patches (",
"    <a class=\"graphic graphic_picture graphicRef71583 graphicRef58252 \" href=\"UTD.htm?41/9/42137\">",
"     picture 3A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Tinea capitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scaling is present (",
"    <a class=\"graphic graphic_picture graphicRef86628 graphicRef86686 \" href=\"UTD.htm?32/17/33050\">",
"     picture 7A-B",
"    </a>",
"    ). Look for adenopathy or erythema. Potassium hydroxide (KOH) prep shows hyphae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"     \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment/patient education",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For traction alopecia, decrease tension on hair roots by altering styling techniques, avoiding styling practices that require tension on the hair (eg, rollers, hot combing, braiding hair tightly).",
"     </li>",
"     <li>",
"      For chemically-induced hair breakage, discontinue use of harsh chemicals on the hair, such as chemical hair straighteners.",
"     </li>",
"     <li>",
"      Identify any habits or tics causing trichotillomania. Cognitive behavioral therapy usually is successful if the patient is recalcitrant to education [",
"      <a class=\"abstract\" href=\"UTD.htm?13/33/13846/abstract/13\">",
"       13",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link\">",
"       \"Overview of psychotherapies\"",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      hydrochloride (Prozac) 20 to 40 mg a day in adults or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"       clomipramine",
"      </a>",
"      (Anafranil) 25 to 250",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in adults or a maximum of 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in children have had variable success for alleviating compulsive hair pulling [",
"      <a class=\"abstract\" href=\"UTD.htm?13/33/13846/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. In a 12-week placebo-controlled randomized trial of 50 adults with trichotillomania, N-acetylcysteine (1200 to 2400",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was associated with statistically significant reductions in symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?13/33/13846/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Regrowth of hair cannot be evaluated for several months. Hair loss may be permanent if traction alopecia or trichotillomania is longstanding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=see_link\">",
"       \"Patient information: Hair loss from cancer treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/56/17282?source=see_link\">",
"       \"Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/15/24817?source=see_link\">",
"       \"Patient information: Alopecia areata (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H560888\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonscarring hair loss is hair loss that occurs in the absence of permanent destruction of the hair follicle. Examples of disorders characterized by nonscarring hair loss include anagen effluvium, androgenetic alopecia, telogen effluvium, alopecia areata, and certain types of traumatic alopecia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link\">",
"       \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link\">",
"       \"Treatment of androgenetic alopecia in men\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link\">",
"       \"Clinical manifestations and diagnosis of alopecia areata\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hair follicles grow in a cyclic pattern that is divided into three phases: anagen (growth), catagen (involution), and telogen (resting). The majority of hair follicles on the scalp are in the anagen phase, which typically lasts for two to eight years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hair growth cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Telogen effluvium is the most common cause of diffuse nonscarring hair loss, and can often be linked to a preceding psychologically or physically stressful event. In telogen effluvium, noticeable hair loss usually occurs three to four months after the onset of the stressor. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Telogen effluvium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hair loss also may result from trichotillomania, direct damage to the hair shaft, or chronic tension applied to hair. Persistent insults to the hair follicle may eventually result in the permanent loss of hair. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Traumatic alopecia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/1\">",
"      Hunt N, McHale S. The psychological impact of alopecia. BMJ 2005; 331:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/2\">",
"      Price VH. Treatment of hair loss. N Engl J Med 1999; 341:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/3\">",
"      Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999; 341:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/4\">",
"      Higgins CA, Westgate GE, Jahoda CA. From telogen to exogen: mechanisms underlying formation and subsequent loss of the hair club fiber. J Invest Dermatol 2009; 129:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/5\">",
"      Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol 1993; 129:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/6\">",
"      Whiting DA. Chronic telogen effluvium. Dermatol Clin 1996; 14:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/7\">",
"      Blume-Peytavi U, Blumeyer A, Tosti A, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 2011; 164:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/8\">",
"      Birch MP, Lalla SC, Messenger AG. Female pattern hair loss. Clin Exp Dermatol 2002; 27:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/9\">",
"      Llau ME, Viraben R, Montastruc JL. [Drug-induced alopecia: review of the literature]. Therapie 1995; 50:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/10\">",
"      Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol 2006; 54:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/11\">",
"      Olsen EA. Iron deficiency and hair loss: the jury is still out. J Am Acad Dermatol 2006; 54:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/12\">",
"      Olsen EA, Reed KB, Cacchio PB, Caudill L. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. J Am Acad Dermatol 2010; 63:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/13\">",
"      Ninan PT, Rothbaum BO, Marsteller FA, et al. A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. J Clin Psychiatry 2000; 61:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/14\">",
"      Winchel RM, Jones JS, Stanley B, et al. Clinical characteristics of trichotillomania and its response to fluoxetine. J Clin Psychiatry 1992; 53:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/15\">",
"      Streichenwein SM, Thornby JI. A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry 1995; 152:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13846/abstract/16\">",
"      Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2009; 66:756.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3322 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13846=[""].join("\n");
var outline_f13_33_13846=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H560888\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HAIR GROWTH CYCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANDROGENETIC ALOPECIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ALOPECIA AREATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TELOGEN EFFLUVIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Anagen effluvium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Androgenetic alopecia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TRAUMATIC ALOPECIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Alopecia areata",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Tinea capitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment/patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H560888\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/3322\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/3322|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/12/2255\" title=\"figure 1\">",
"      Telogen and anagen hairs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/3322|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/52/31559\" title=\"picture 1A\">",
"      Androgenetic alopecia vertex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/47/40692\" title=\"picture 1B\">",
"      Androgenetic alopecia extensive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/50/6950\" title=\"picture 1C\">",
"      Androgenetic alopecia bitemporal recession",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/36/29253\" title=\"picture 2\">",
"      Androgenetic alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/46/23271\" title=\"picture 3A\">",
"      Alopecia areata 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/18/40226\" title=\"picture 3B\">",
"      Alopecia areata 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/36/9792\" title=\"picture 4\">",
"      Telogen effluvium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/36/38468\" title=\"picture 5\">",
"      Traction alopecia hairline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/30/2535\" title=\"picture 6\">",
"      Trichotillomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/47/9976\" title=\"picture 7A\">",
"      Tinea capitis - black dot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/35/26167\" title=\"picture 7B\">",
"      Tinea capitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/3322|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/47/15099\" title=\"table 1\">",
"      Examples of medications associated with hair loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=related_link\">",
"      Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44232?source=related_link\">",
"      Chemotherapy-induced alopecia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=related_link\">",
"      Clinical manifestations and diagnosis of alopecia areata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9690?source=related_link\">",
"      Evaluation and diagnosis of hair loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31752?source=related_link\">",
"      Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14344?source=related_link\">",
"      Female pattern hair loss (androgenetic alopecia in women): Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4330?source=related_link\">",
"      Management of alopecia areata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/15/24817?source=related_link\">",
"      Patient information: Alopecia areata (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/56/17282?source=related_link\">",
"      Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=related_link\">",
"      Treatment of androgenetic alopecia in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_33_13847="Chronic pancreatitis Light";
var content_f13_33_13847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph from a patient with chronic pancreatitis. There are bands of fibrosis (stained in red) and scattered mononuclear cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven D Freedman, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13847=[""].join("\n");
var outline_f13_33_13847=null;
var title_f13_33_13848="Epidemiology and diagnosis of hantavirus infections";
var content_f13_33_13848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and diagnosis of hantavirus infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/33/13848/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13848/contributors\">",
"     Brian Hjelle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/33/13848/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13848/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/33/13848/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13848/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/33/13848/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hantaviruses comprise a genus of enveloped viruses within the family Bunyaviridae. All medically important hantaviruses are carried by rodents of the families Muridae and Cricetidae. These pathogens are associated with two severe, acute febrile illnesses:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemorrhagic fever with renal syndrome (HFRS, caused by viruses of the Old World)",
"     </li>",
"     <li>",
"      Hantavirus cardiopulmonary syndrome (HCPS, caused by viruses of the New World), also known as hantavirus pulmonary syndrome (HPS)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology and diagnosis of hantavirus infections, with a special emphasis on HCPS, will be reviewed here. The clinical manifestations, pathogenesis, and prevention of hantavirus infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=see_link\">",
"     \"Hantavirus cardiopulmonary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25544?source=see_link\">",
"     \"Renal involvement with hantavirus infection (hemorrhagic fever with renal syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4920?source=see_link\">",
"     \"Pathogenesis of hantavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise number of identified hantavirus species is a matter of debate, but at least 20 distinct viral species exist in nature; at least 11 are associated with human disease (",
"    <a class=\"graphic graphic_table graphicRef53589 \" href=\"UTD.htm?17/32/17933\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hantaviruses have single-stranded, negative-sense RNA genomes that are divided into three segments. The L, or large segment, encodes a replicative enzyme, RNA-dependent RNA polymerase; the M (middle) segment encodes the envelope glycoproteins G1 and G2, and the S segment encodes the nucleocapsid protein N.",
"   </p>",
"   <p>",
"    The envelope glycoproteins may mediate attachment to cells via the beta-3-integrin cell-surface molecule, which is found on endothelial cells and platelets throughout the body [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Hantaviruses also infect vascular endothelial cells in vivo. A broader tropism to Kupffer cells and renal epithelium has been demonstrated by some hantaviruses in animal models and humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RODENT RESERVOIRS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each hantavirus is specifically associated with a single species of wild rodent, which serves as its primary natural reservoir. Approximately 5 to 20 percent of rodents of the predominant carrier species demonstrate anti-hantavirus antibodies and are usually viremic. Hantaviruses have a worldwide distribution, in accordance with the habitats of their respective hosts.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those that cause hemorrhagic fever with renal syndrome (HFRS) are carried by field mice, except for Puumala virus, which is carried by a vole.",
"     </li>",
"     <li>",
"      Many native rodents of North and South America carry the etiologic agents of hantavirus cardiopulmonary syndrome (HCPS). The deer mouse is the major reservoir of the Sin Nombre Virus, the most important cause of this syndrome in North America.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The viruses that cause HCPS are more closely related to one another than they are to any of the etiologic agents of HFRS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The observation that closely-related viruses infect closely-related hosts and cause similar clinical syndromes has led to the belief that hantaviruses have co-evolved over many millennia within their predominant reservoir host species [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rodent contact is an important factor in the transmission of hantaviruses to humans. Many hantaviruses are shed in the urine, feces, or saliva of acutely infected reservoir rodents. It is suspected that much, if not all, transmission to humans occurs via the aerosol route, even if the exact nature of the aerosol is difficult to establish.",
"   </p>",
"   <p>",
"    Very few patients who contract hantaviruses describe recent rodent bites. However, two to four weeks before they develop symptoms, many describe encountering living or dead rodents or entry into rooms with visible evidence of rodent infestation. Indoor exposure may be especially important. As an example, virtually all patients infected with the Sin Nombre hantavirus in the United States had documented indoor exposure inside rodent-infested buildings [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/4\">",
"     4",
"    </a>",
"    ]. However, studies have differed in the extent to which they specifically addressed indoor compared with outdoor exposures. Seroepidemiologic studies suggest that the risk of infection with hantaviruses is low in persons with occupational rodent contact in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Informative examples of laboratory-acquired infections of hemorrhagic fever with renal syndrome (HFRS) have been studied in Europe, Asia, and especially in Russia. In a Russian outbreak in 1961, 113 cases were linked to the housing of hantavirus-infected rodents in very poorly-ventilated, poorly-maintained animal research facilities. A number of laboratory-associated cases have involved individuals whose closest contact with rodents consisted of brief entry into laboratories that were housing infected reservoir rodents. It is the large number of such cases that support the belief that airborne transmission is the normal route of exposure for man [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Person-to-person transmission of hantaviruses is rare and has been confined only to a single hantavirus species, Andes virus. It is sometimes difficult to distinguish between interpersonal transmission among family members and common-source exposure to rodents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The interval between exposure and the onset of symptoms for hantavirus infections range from one to six weeks, with a median of 14 to 17 days. Secondary cases that occur within seven days of a primary case are generally ascribed to common-source exposures rather than interpersonal transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One prospective study of 476 household contacts of 76 persons with Andes virus infection in Chile demonstrated that the risk of hantavirus cardiopulmonary syndrome (HCPS) was 17.6 percent among sexual partners of the index case patient versus 1.2 percent among other household contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/9\">",
"     9",
"    </a>",
"    ]. Viral RNA was detected by reverse transcriptase polymerase chain reaction in peripheral blood mononuclear cells 5 to 15 days before the onset of symptoms or specific antibodies. Discovery of hantavirus RNA in the saliva of patients with Puumala virus-induced HFRS has suggested that there may be a risk of transmission from oral secretions, but live virus was not detected in saliva and epidemiologic findings do not support such a concern [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     THE RECOGNITION OF HANTAVIRUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hantavirus outbreaks have probably occurred for centuries. After hantavirus illness was recognized by Western medicine, a review of centuries-old Chinese writings revealed descriptions of compatible syndromes dating to approximately 960 AD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The event that brought hemorrhagic fever with renal syndrome (HFRS) to the attention of Western medicine was a carefully described outbreak among United Nations troops between 1951 and 1953 during the Korean conflict. More than 2000 troops were afflicted, with a case-fatality rate of about 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/12\">",
"     12",
"    </a>",
"    ]. Rodents were suspected to be involved in the epidemiology, but more than two decades passed before the etiologic agent, Hantaan virus, was isolated from a striped field mouse [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/13\">",
"     13",
"    </a>",
"    ]. In the next several years, other etiologic agents of HFRS were identified in Korea (Seoul virus) and Europe (Puumala and Dobrava viruses) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serologic surveys for hantavirus exposure in rodent populations suggested that hantaviruses were widespread in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/17\">",
"     17",
"    </a>",
"    ]. However, the discovery of hantavirus cardiopulmonary syndrome (HCPS) was unanticipated by investigators, who had been searching for HFRS in the New World. In the 1980s, Seoul virus and a new species of hantavirus, Prospect Hill virus, were isolated in the United States from the commensal rat, Rattus norvegicus, and a vole species, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. After a decade-long search, a very small number of human cases of HFRS due to Seoul virus were identified in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/20\">",
"     20",
"    </a>",
"    ]. Such cases appear to be very rare [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the spring of 1993, an alarming series of cases of unexplained fever and acute respiratory distress syndrome (ARDS) were recognized among members of the Navajo tribe at the northern border between New Mexico and Arizona [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/23\">",
"     23",
"    </a>",
"    ]. The case-fatality rate was approximately 80 percent in the initial group of patients. Serum samples from these patients contained IgM antibodies that reacted against hantavirus isolates from Korea and Finland. In the subsequent weeks, the newly-identified Sin Nombre virus was proven to be the etiologic agent for HCPS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. Investigators subsequently identified other new hantaviruses as etiologic agents of rare cases of HCPS in the United States and as common etiologic agents of HCPS in South and Central America [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/29-34\">",
"     29-34",
"    </a>",
"    ]. Cases have been identified in 32 states in the United States since the 1993 outbreak [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/35\">",
"     35",
"    </a>",
"    ], with the majority of cases occurring in non-Native Americans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     WORLDWIDE PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that many cases of hantavirus disease go unreported, due in part to clinical confusion with leptospirosis, dengue fever, malaria, and other entities, especially in tropical regions. China bears the highest annual incidence by far of hantavirus disease. From 16,000 to 100,000 or more cases of hemorrhagic fever with renal syndrome (HFRS) are reported every year in China, and thousands more cases may occur in Russia (",
"    <a class=\"graphic graphic_table graphicRef53589 \" href=\"UTD.htm?17/32/17933\">",
"     table 1",
"    </a>",
"    ). Chinese cases of HFRS are most commonly caused by Seoul virus, with some cases caused by Hantaan virus.",
"   </p>",
"   <p>",
"    Several thousand cases of HFRS due to Puumala and Dobrava viruses occur annually throughout Europe, but accurate counts are unavailable. Case-fatality rates range from &lt;1 percent for nephropathia epidemica (Puumala virus-HFRS) to 2 to 10 percent (Hantaan or Dobrava viruses) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/2\">",
"     2",
"    </a>",
"    ]. Case-fatality rates in China are 1 percent, with women having slightly higher mortality rates than men [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/36\">",
"     36",
"    </a>",
"    ]. In 2012, two cases of HFRS due to Seoul virus were detected in the United Kingdom; one was traced to wild rats and the other to pet rats [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. As noted above, HFRS due to Seoul virus has also been observed rarely in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'The recognition of hantaviruses'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As of February 2013, only 617 cases of hantavirus cardiopulmonary syndrome (HCPS) had been documented in the United States, including a few that were retrospectively recognized after the disease was identified in 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/35,39-43\">",
"     35,39-43",
"    </a>",
"    ]. Increased numbers of HCPS cases were reported in the United States from January through March 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/44\">",
"     44",
"    </a>",
"    ], as well as from 1993 to 1994 and 1999 to 2000.",
"   </p>",
"   <p>",
"    An outbreak of hantavirus infection occurred among 10 visitors to Yosemite National Park in California during the summer of 2012, including nine cases of HCPS and three fatal cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/45\">",
"     45",
"    </a>",
"    ]. Nine patients had stayed in one group of insulated tent cabins. Rodent infestations were discovered in the insulation.",
"   </p>",
"   <p>",
"    Canada reports 10 to 15 percent of North American cases each year. Other countries that have experienced hantavirus activity include Argentina, Chile, Panama, Paraguay, Uruguay, Brazil, and Bolivia. Collectively, more than 3000 cases of HCPS have been identified throughout the Americas, far less than the Eurasian total for HFRS. However, the case-fatality ratios are much higher for HCPS than for HFRS, typically ranging from 25 to 50 percent. Treatment is generally unsatisfactory for HCPS, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    may be effective against HFRS due to Hantaan virus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=see_link\">",
"     \"Hantavirus cardiopulmonary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In all countries affected by hantavirus disease, there are regions that exhibit a high incidence of infection and others that are only rarely affected. In the United States, there are many more cases in the western states such as New Mexico, California, Washington, and Texas than in the Midwestern or Eastern states. Climatic influences imposed, for example, by the El Ni&ntilde;o Southern Oscillation (ENSO), are thought to be important factors in the incidence of hantavirus disease, but the mechanism by which ENSO influences the incidence of HCPS remains a matter of speculation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SEROPREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human past exposure to hantaviruses, as determined by the presence of specific IgG antibodies, varies greatly throughout the world. Epidemiologic data are conflicting regarding the incidence of asymptomatic infections. The ratio of symptomatic to asymptomatic infection for Hantaan virus was approximately one to five in the single population-based study that attempted to quantify this ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/46\">",
"     46",
"    </a>",
"    ]. In contrast, in other regions the ratio of symptomatic infections to total infections is quite low. While indigenous populations of the Paraguayan Chaco have seroprevalences of 40 percent, clinical onset of hantavirus cardiopulmonary syndrome (HCPS) is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Similar high prevalence has been reported in Panama [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear whether differences in the host or variations in virulence among the hantaviruses explain the variation in the incidence of infection and disease presentation. In the United States, the most affected populations in the Four Corners states have a seroprevalence of approximately one percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. However, the adult population of the United States is believed to have a seroprevalence of less than 0.1 percent [unpublished data]. Children uncommonly present with hemorrhagic fever with renal syndrome or HCPS, except in South America where children as young as five years of age have died of HCPS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/53\">",
"     53",
"    </a>",
"    ]. In 2009, five cases of HCPS were reported among children in the western United States [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SEASONALITY AND CYCLICITY OF HANTAVIRUS ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hantavirus infections occur in seasonal outbreaks, which vary substantially in incidence from year to year and from site to site.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chinese outbreaks of hemorrhagic fever with renal syndrome (HFRS) occur in the spring as crops are planted and a second, larger cluster of cases follows in the fall. At that time, workers are involved in the fall harvest and may become exposed by sleeping in poorly sealed huts with rodent infestations.",
"     </li>",
"     <li>",
"      In Scandinavia, cyclical outbreaks of HFRS occur every several years and appear to be immediately preceded by irruptions of wild voles [",
"      <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Chile, a 2001 outbreak of human disease was associated with an abrupt increase in abundance of the colilarga (Oligoryzomys longicaudatus), the reservoir for Andes virus [",
"      <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATTERNS OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well over 90 percent of United States and Canadian cases of hantavirus cardiopulmonary syndrome (HCPS) are sporadic, even though other persons can often be identified as having engaged in same \"high risk\" activities as the index case.",
"   </p>",
"   <p>",
"    By contrast, approximately 25 to 30 percent of cases of hantavirus cardiopulmonary syndrome (HCPS) in Chile occur in clusters [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/56\">",
"     56",
"    </a>",
"    ]. It is usually presumed that these cluster cases patients were exposed to a common source, such as an infectious rodent that was actively shedding an unusually large amount of virus. However, person-to-person transmission has been suspected in some patients who developed symptoms many days or weeks after those of the index patient in locations distant from the rodent infestation.",
"   </p>",
"   <p>",
"    Cases of HCPS have occurred during pregnancy. In one series, the clinical presentation did not differ for five pregnant patients compared to historical controls with HCPS who were not pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/57\">",
"     57",
"    </a>",
"    ]. One maternal and two fetal deaths were reported, but no evidence of vertical transmission of Sin Nombre virus was documented. Breast milk can be positive for Sin Nombre virus RNA, but breastfeeding has not been linked to transmission of virus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic methods are preferred for diagnosis of either human or rodent hantavirus infections in most laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serologic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests are the main methods for diagnosis of either acute or remote infection by hantaviruses, although none has been approved by the US Food and Drug Administration. By the time symptoms are evident, patients uniformly have antiviral antibodies of the IgM class and most have antibodies of the IgG class [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Diagnostic assays include: enzyme linked immunosorbent assays (ELISA), strip immunoblot tests (SIA), Western blot, indirect immunofluorescence (IFA), complement fixation, hemagglutinin inhibition, as well as focus or plaque reduction neutralization tests to detect antibodies to hantaviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute infection can be distinguished from remote (past) infection by the presence of specific anti-hantavirus IgM in the former (usually the nucleocapsid or N antigen is used) or a fourfold rise in titers of anti-hantavirus IgG. Sin Nombre virus (SNV) infection can be distinguished from infections by other hantaviruses with the SIA by virtue of the reaction of anti-SNV serum samples against the SNV Gn antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, those state health departments that offer hantavirus diagnostic testing use IgG and mu-capture IgM ELISAs developed and distributed by the CDC. These ELISAs use recombinantly-expressed N antigen. This test has also been used in Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/60\">",
"     60",
"    </a>",
"    ]. A Western blot assay using recombinant antigens and isotype-specific conjugates for IgM-IgG differentiation has also been developed, which performs similarly.",
"   </p>",
"   <p>",
"    Hantaan virus and Seoul virus infections are often diagnosed in the Asian centers where hemorrhagic fever with renal syndrome (HFRS) occurs using bead agglutination (HantaDia), ELISA, and IFA formats [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/62\">",
"     62",
"    </a>",
"    ]. European laboratories favor ELISA, with some using protein antigens synthesized through recombinant DNA technology, although IFA is still used by some [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. South American reference laboratories usually use ELISA or, in some cases, SIA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;For hantaviruses that cause fulminant infection with high case-fatality rates (Andes, Sin Nombre, Dobrava, and possibly Hantaan viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/68\">",
"     68",
"    </a>",
"    ]), it is generally possible to detect viral RNA by nested reverse transcriptase-polymerase chain reaction (RT-PCR) using peripheral blood mononuclear cells (PBMC) or serum during the early stages of pulmonary disease. However, viral RNA usually disappears from the circulation after a few days and serologic techniques have high diagnostic accuracy.",
"   </p>",
"   <p>",
"    For the milder infections caused by Puumala virus, RNA can be detected in only a small minority of patients, ie, those who have an unusually severe infection. For these reasons, few if any clinical laboratories offer a routine RT-PCR diagnostic test. RT-PCR is more useful as a backup or confirmatory diagnostic test, or for identifying possible sites of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Autopsy testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;At autopsy, viral antigen can be readily detected by immunohistochemistry using antibodies to the viral N antigen. The N antigen stains in a cytoplasmic, punctuate pattern and localizes especially to the vascular endothelium in lungs and the glomerular capillary endothelium in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Nested RT-PCR can be used to detect viral RNA in frozen or even fixed, paraffin-embedded tissues obtained at necropsy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/25,28\">",
"     25,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MOLECULAR EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of individual viral genetic sequences has been used as an investigational tool for molecular epidemiologic research. While it appears that particular viral genotypes may remain stable in a given, small geographic area for years, it is very unlikely that one will encounter two viruses of identical sequence across a distance of several kilometers or more [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/71\">",
"     71",
"    </a>",
"    ]. Thus, RT-PCR amplification followed by DNA sequencing of the PCR product from a human sample can provide useful information about the viral species involved and the precise site of exposure. By comparing the viral cDNA sequence from a given patient with those obtained from nearby infected rodents, or even from other patients in the region, it may be possible to distinguish infections acquired peridomestically from those acquired at a workplace.",
"   </p>",
"   <p>",
"    To conduct this type of investigation, it is necessary to collect at least 3 to 10 seropositive rodents from each candidate site of exposure. In the experience of the University of New Mexico's Center for Infectious Diseases and Immunity, a virus of identical sequence to that of the case-patient can be identified in at least two of three attempts where an adequate investigation is completed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13848/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both Old World (hemorrhagic fever with renal syndrome) and New World (hantavirus cardiopulmonary syndrome) hantaviruses are carried and transmitted by wild rodents. Infections come in endemic and epidemic forms, often in response to natural rodent irruptions. Eleven pathogenic species of hantavirus have been identified throughout the world, with distributions corresponding to those of their rodent carriers (",
"      <a class=\"graphic graphic_table graphicRef53589 \" href=\"UTD.htm?17/32/17933\">",
"       table 1",
"      </a>",
"      ). Patients acquire the infection via aerosols of rodent excreta, usually in closed, poorly ventilated buildings or during cleaning. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Rodent reservoirs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      China bears the highest annual incidence of hantavirus disease. From 16,000 to 100,000 or more cases of hemorrhagic fever with renal syndrome (HFRS) are reported every year in China, and thousands more cases may occur in Russia. By comparison, only 560 cases of hantavirus cardiopulmonary syndrome (HCPS) have been documented in the United States. Hantavirus infections also occur in other parts of the world, such as Europe and South America (",
"      <a class=\"graphic graphic_table graphicRef53589 \" href=\"UTD.htm?17/32/17933\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Worldwide prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Case-fatality rates are highly dependent upon the species of virus. In some regions of the world, there is evidence for considerable numbers of asymptomatic or subclinical infection, but in other regions, it is difficult to find persons who have been exposed without a history of disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'The recognition of hantaviruses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Worldwide prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serologic tests are the main methods for diagnosis of either acute or remote infection by hantaviruses. By the time symptoms are evident, patients uniformly have antiviral antibodies of the IgM class and most have antibodies of the IgG class. Acute infection can be distinguished from remote (past) infection by the presence of specific anti-hantavirus IgM in the former (usually the nucleocapsid or N antigen is used) or a fourfold rise in titers of anti-hantavirus IgG. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Serologic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For hantaviruses that cause fulminant infection with high case-fatality rates (Andes, Sin Nombre, Dobrava, and possibly Hantaan viruses), it is generally possible to detect viral RNA by nested reverse transcriptase-polymerase chain reaction (RT-PCR) using peripheral blood mononuclear cells (PBMC) or serum during the early stages of pulmonary disease. However, viral RNA usually disappears from the circulation after a few days. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Polymerase chain reaction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/1\">",
"      Gavrilovskaya IN, Shepley M, Shaw R, et al. beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci U S A 1998; 95:7074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/2\">",
"      Schmaljohn C, Hjelle B. Hantaviruses: a global disease problem. Emerg Infect Dis 1997; 3:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/3\">",
"      Peters CJ, Khan AS. Hantavirus pulmonary syndrome: the new American hemorrhagic fever. Clin Infect Dis 2002; 34:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/4\">",
"      Hjelle B, Glass GE. Outbreak of hantavirus infection in the Four Corners region of the United States in the wake of the 1997-1998 El Nino-southern oscillation. J Infect Dis 2000; 181:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/5\">",
"      Fulhorst CF, Milazzo ML, Armstrong LR, et al. Hantavirus and arenavirus antibodies in persons with occupational rodent exposure. Emerg Infect Dis 2007; 13:532.",
"     </a>",
"    </li>",
"    <li>",
"     Trencs&eacute;ni, T, Keleti, B. Clinical aspects and epidemiology of haemorrhagic fever with renal syndrome. Budapest: Akad&eacute;mai Kiad&oacute;, 1971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/7\">",
"      Padula PJ, Edelstein A, Miguel SD, et al. [Epidemic outbreak of Hantavirus pulmonary syndrome in Argentina. Molecular evidence of person to person transmission of Andes virus]. Medicina (B Aires) 1998; 58 Suppl 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/8\">",
"      Young JC, Hansen GR, Graves TK, et al. The incubation period of hantavirus pulmonary syndrome. Am J Trop Med Hyg 2000; 62:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/9\">",
"      Ferres M, Vial P, Marco C, et al. Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile. J Infect Dis 2007; 195:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/10\">",
"      Pettersson L, Klingstr&ouml;m J, Hardestam J, et al. Hantavirus RNA in saliva from patients with hemorrhagic fever with renal syndrome. Emerg Infect Dis 2008; 14:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/11\">",
"      Lee HW, van der Groen G. Hemorrhagic fever with renal syndrome. Prog Med Virol 1989; 36:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/12\">",
"      SHEEDY JA, FROEB HF, BATSON HA, et al. The clinical course of epidemic hemorrhagic fever. Am J Med 1954; 16:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/13\">",
"      Lee HW, Lee PW, Johnson KM. Isolation of the etiologic agent of Korean Hemorrhagic fever. J Infect Dis 1978; 137:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/14\">",
"      Lee HW, Baek LJ, Johnson KM. Isolation of Hantaan virus, the etiologic agent of Korean hemorrhagic fever, from wild urban rats. J Infect Dis 1982; 146:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/15\">",
"      Brummer-Korvenkontio M, Vaheri A, Hovi T, et al. Nephropathia epidemica: detection of antigen in bank voles and serologic diagnosis of human infection. J Infect Dis 1980; 141:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/16\">",
"      Avsic-Zupanc T, Xiao SY, Stojanovic R, et al. Characterization of Dobrava virus: a Hantavirus from Slovenia, Yugoslavia. J Med Virol 1992; 38:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/17\">",
"      Tsai TF, Bauer SP, Sasso DR, et al. Serological and virological evidence of a Hantaan virus-related enzootic in the United States. J Infect Dis 1985; 152:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/18\">",
"      LeDuc JW, Smith GA, Johnson KM. Hantaan-like viruses from domestic rats captured in the United States. Am J Trop Med Hyg 1984; 33:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/19\">",
"      Lee PW, Goldgaber D, Gibbs CJ Jr, et al. Other serotypes of hemorrhagic fever with renal syndrome viruses in Europe. Lancet 1982; 2:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/20\">",
"      Glass GE, Watson AJ, LeDuc JW, Childs JE. Domestic cases of hemorrhagic fever with renal syndrome in the United States. Nephron 1994; 68:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/21\">",
"      Woods C, Palekar R, Kim P, et al. Domestically acquired seoul virus causing hemorrhagic fever with renal syndrome-Maryland, 2008. Clin Infect Dis 2009; 49:e109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/22\">",
"      Roig IL, Musher DM, Tweardy DJ. Severe pulmonary involvement in a case attributed to domestically acquired Seoul hantavirus in the United States. Clin Infect Dis 2012; 54:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/23\">",
"      From the Centers for Disease Control and Prevention. Infectious diseases update: outbreak, hantavirus infection--southwestern United States, 1993. JAMA 1993; 270:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/24\">",
"      Jenison S, Hjelle B, Simpson S, et al. Hantavirus pulmonary syndrome: clinical, diagnostic, and virologic aspects. Semin Respir Infect 1995; 10:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/25\">",
"      Nichol ST, Spiropoulou CF, Morzunov S, et al. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science 1993; 262:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/26\">",
"      Chizhikov VE, Spiropoulou CF, Morzunov SP, et al. Complete genetic characterization and analysis of isolation of Sin Nombre virus. J Virol 1995; 69:8132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/27\">",
"      Hjelle B, Jenison S, Mertz G, et al. Emergence of hantaviral disease in the southwestern United States. West J Med 1994; 161:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/28\">",
"      Hjelle B, Jenison S, Torrez-Martinez N, et al. A novel hantavirus associated with an outbreak of fatal respiratory disease in the southwestern United States: evolutionary relationships to known hantaviruses. J Virol 1994; 68:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/29\">",
"      Johnson AM, Bowen MD, Ksiazek TG, et al. Laguna Negra virus associated with HPS in western Paraguay and Bolivia. Virology 1997; 238:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/30\">",
"      Hjelle B, Krolikowski J, Torrez-Martinez N, et al. Phylogenetically distinct hantavirus implicated in a case of hantavirus pulmonary syndrome in the northeastern United States. J Med Virol 1995; 46:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/31\">",
"      L&oacute;pez N, Padula P, Rossi C, et al. Genetic identification of a new hantavirus causing severe pulmonary syndrome in Argentina. Virology 1996; 220:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/32\">",
"      Morzunov SP, Feldmann H, Spiropoulou CF, et al. A newly recognized virus associated with a fatal case of hantavirus pulmonary syndrome in Louisiana. J Virol 1995; 69:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/33\">",
"      Rollin PE, Ksiazek TG, Elliott LH, et al. Isolation of black creek canal virus, a new hantavirus from Sigmodon hispidus in Florida. J Med Virol 1995; 46:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/34\">",
"      Vincent MJ, Quiroz E, Gracia F, et al. Hantavirus pulmonary syndrome in Panama: identification of novel hantaviruses and their likely reservoirs. Virology 2000; 277:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: hantavirus pulmonary syndrome --- Maine, April 2011. MMWR Morb Mortal Wkly Rep 2011; 60:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/36\">",
"      Klein SL, Marks MA, Li W, et al. Sex differences in the incidence and case fatality rates from hemorrhagic fever with renal syndrome in China, 2004-2008. Clin Infect Dis 2011; 52:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/37\">",
"      Jameson LJ, Logue CH, Atkinson B, et al. The continued emergence of hantaviruses: isolation of a Seoul virus implicated in human disease, United Kingdom, October 2012. Euro Surveill 2013; 18:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/38\">",
"      Taori SK, Jameson LJ, Campbell A, et al. UK hantavirus, renal failure, and pet rats. Lancet 2013; 381:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/39\">",
"      Zaki SR, Khan AS, Goodman RA, et al. Retrospective diagnosis of hantavirus pulmonary syndrome, 1978-1993: implications for emerging infectious diseases. Arch Pathol Lab Med 1996; 120:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/40\">",
"      Frampton JW, Lanser S, Nichols CR. Sin Nombre virus infection in 1959. Lancet 1995; 346:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/41\">",
"      Wilson C, Hjelle B, Jenison S. Probable hantavirus pulmonary syndrome that occurred in New Mexico in 1975. Ann Intern Med 1994; 120:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/42\">",
"      MacNeil A, Ksiazek TG, Rollin PE. Hantavirus pulmonary syndrome, United States, 1993-2009. Emerg Infect Dis 2011; 17:1195.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. US HPS cases, by state of exposure. file://www.cdc.gov/hantavirus/surveillance/state-of-exposure.html (Accessed on March 29, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/44\">",
"      Centers for Disease Control and Prevention (CDC). Hantavirus pulmonary syndrome--five states, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/45\">",
"      Centers for Disease Control and Prevention (CDC). Hantavirus pulmonary syndrome in visitors to a national park--Yosemite Valley, California, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/46\">",
"      Ruo SL, Li YL, Tong Z, et al. Retrospective and prospective studies of hemorrhagic fever with renal syndrome in rural China. J Infect Dis 1994; 170:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/47\">",
"      Ferrer JF, Jonsson CB, Esteban E, et al. High prevalence of hantavirus infection in Indian communities of the Paraguayan and Argentinean Gran Chaco. Am J Trop Med Hyg 1998; 59:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/48\">",
"      Williams RJ, Bryan RT, Mills JN, et al. An outbreak of hantavirus pulmonary syndrome in western Paraguay. Am J Trop Med Hyg 1997; 57:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/49\">",
"      Armien B, Pascale JM, Bayard V, et al. High seroprevalence of hantavirus infection on the Azuero peninsula of Panama. Am J Trop Med Hyg 2004; 70:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/50\">",
"      Gonzalez LM, Lindsey AE, Hjelle B, et al. Prevalence of antibodies to Sin Nombre virus in humans living in rural areas of southern New Mexico and western Texas. Virus Res 2001; 74:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/51\">",
"      Hjelle B, Jenison S, Torrez-Martinez N, et al. Rapid and specific detection of Sin Nombre virus antibodies in patients with hantavirus pulmonary syndrome by a strip immunoblot assay suitable for field diagnosis. J Clin Microbiol 1997; 35:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/52\">",
"      Centers for Disease Control and Prevention (CDC). Hantavirus pulmonary syndrome in five pediatric patients - four states, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/53\">",
"      Pini NC, Resa A, del Jes&uacute;s Laime G, et al. Hantavirus infection in children in Argentina. Emerg Infect Dis 1998; 4:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/54\">",
"      Niklasson B, Hornfeldt B, Lundkvist A, et al. Temporal dynamics of Puumala virus antibody prevalence in voles and of nephropathia epidemica incidence in humans. Am J Trop Med Hyg 1995; 53:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/55\">",
"      Castillo C, Naranjo J, Sep&uacute;lveda A, et al. Hantavirus pulmonary syndrome due to Andes virus in Temuco, Chile: clinical experience with 16 adults. Chest 2001; 120:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/56\">",
"      Toro J, Vega JD, Khan AS, et al. An outbreak of hantavirus pulmonary syndrome, Chile, 1997. Emerg Infect Dis 1998; 4:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/57\">",
"      Howard MJ, Doyle TJ, Koster FT, et al. Hantavirus pulmonary syndrome in pregnancy. Clin Infect Dis 1999; 29:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/58\">",
"      Pai RK, Bharadwaj M, Levy H, et al. Absence of infection in a neonate after possible exposure to sin nombre hantavirus in breast milk. Clin Infect Dis 1999; 29:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/59\">",
"      Bharadwaj M, Nofchissey R, Goade D, et al. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis 2000; 182:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/60\">",
"      Ksiazek TG, Peters CJ, Rollin PE, et al. Identification of a new North American hantavirus that causes acute pulmonary insufficiency. Am J Trop Med Hyg 1995; 52:117.",
"     </a>",
"    </li>",
"    <li>",
"     Hjelle B. Hantavirus pulmonary syndrome. In: Laboratory Diagnosis of Viral Infections, Lennette EH, Smith TF (Eds), Marcel Decker, New York 1999. p.421.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/62\">",
"      Lee HW. Korean hemorrhagic fever. Prog Med Virol 1982; 28:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/63\">",
"      Elgh F, Lundkvist A, Alexeyev OA, et al. Serological diagnosis of hantavirus infections by an enzyme-linked immunosorbent assay based on detection of immunoglobulin G and M responses to recombinant nucleocapsid proteins of five viral serotypes. J Clin Microbiol 1997; 35:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/64\">",
"      Kallio-Kokko H, Lundkvist A, Plyusnin A, et al. Antigenic properties and diagnostic potential of recombinant dobrava virus nucleocapsid protein. J Med Virol 2000; 61:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/65\">",
"      Sj&ouml;lander KB, Elgh F, Kallio-Kokko H, et al. Evaluation of serological methods for diagnosis of Puumala hantavirus infection (nephropathia epidemica). J Clin Microbiol 1997; 35:3264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/66\">",
"      Vapalahti O, Kallio-Kokko H, N&auml;rv&auml;nen A, et al. Human B-cell epitopes of Puumala virus nucleocapsid protein, the major antigen in early serological response. J Med Virol 1995; 46:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/67\">",
"      Padula PJ, Rossi CM, Della Valle MO, et al. Development and evaluation of a solid-phase enzyme immunoassay based on Andes hantavirus recombinant nucleoprotein. J Med Microbiol 2000; 49:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/68\">",
"      Saksida A, Duh D, Korva M, Avsic-Zupanc T. Dobrava virus RNA load in patients who have hemorrhagic fever with renal syndrome. J Infect Dis 2008; 197:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/69\">",
"      Zaki SR, Greer PW, Coffield LM, et al. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol 1995; 146:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/70\">",
"      Green W, Feddersen R, Yousef O, et al. Tissue distribution of hantavirus antigen in naturally infected humans and deer mice. J Infect Dis 1998; 177:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13848/abstract/71\">",
"      Hjelle B, T&oacute;rrez-Mart&iacute;nez N, Koster FT, et al. Epidemiologic linkage of rodent and human hantavirus genomic sequences in case investigations of hantavirus pulmonary syndrome. J Infect Dis 1996; 173:781.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8307 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-49B032D4AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13848=[""].join("\n");
var outline_f13_33_13848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RODENT RESERVOIRS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      THE RECOGNITION OF HANTAVIRUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      WORLDWIDE PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SEROPREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SEASONALITY AND CYCLICITY OF HANTAVIRUS ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATTERNS OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serologic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Autopsy testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MOLECULAR EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8307\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8307|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/32/17933\" title=\"table 1\">",
"      Hantavirus worldwide prevalence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=related_link\">",
"      Hantavirus cardiopulmonary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4920?source=related_link\">",
"      Pathogenesis of hantavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25544?source=related_link\">",
"      Renal involvement with hantavirus infection (hemorrhagic fever with renal syndrome)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_33_13849="Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis";
var content_f13_33_13849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/33/13849/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13849/contributors\">",
"     Marlene L Durand, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13849/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/33/13849/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13849/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13849/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/33/13849/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13849/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/33/13849/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27883216\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal endophthalmitis due to yeasts (eg, Candida albicans) differs from that due to molds (eg, Aspergillus or Fusarium spp). Yeast-associated endophthalmitis is usually endogenous (secondary to fungemia) and treatment is often successful, whereas mold endophthalmitis is usually exogenous (occurring after trauma, surgery, or keratomycosis) and often results in permanent loss of vision.",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical features, and diagnosis of fungal endophthalmitis will be reviewed here. The management of fungal endophthalmitis is discussed separately; bacterial endophthalmitis, Fusarium keratitis, and candidemia and other types of Candida infections are also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=see_link\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36102?source=see_link\">",
"     \"Treatment of exogenous endophthalmitis due to Candida species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2937?source=see_link\">",
"     \"Treatment of endophthalmitis due to molds\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=see_link\">",
"     \"Bacterial endophthalmitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link&amp;anchor=H420413563#H420413563\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\", section on 'Keratitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27883231\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"endophthalmitis\" means bacterial or fungal infection within the eye and usually implies infection of the vitreous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aqueous (",
"    <a class=\"graphic graphic_figure graphicRef57690 \" href=\"UTD.htm?41/35/42549\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79279574\">",
"    <span class=\"h2\">",
"     Endogenous fungal endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endogenous fungal endophthalmitis results from fungal seeding of the eye via the bloodstream. In most cases, the highly vascular choroid is seeded first. As a consequence, endogenous fungal endophthalmitis often presents with choroiditis or chorioretinitis (infection localized to the choroid or the choroid and retina), with minimal inflammation in the vitreous or aqueous. As the infection worsens, marked vitritis develops and the aqueous may also become involved. &nbsp;",
"   </p>",
"   <p>",
"    The distinction between fungal choroiditis or chorioretinitis and endophthalmitis (ie, with marked vitritis) is important for making decisions about treatment, and we will specify the degree of involvement in the discussion below. &nbsp;",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79279581\">",
"    <span class=\"h2\">",
"     Exogenous fungal endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous fungal endophthalmitis means that the infection was introduced from the &ldquo;outside,&rdquo; either by eye surgery, eye trauma, or extension of fungal infection of the cornea (termed &ldquo;fungal keratitis&rdquo; or &ldquo;keratomycosis&rdquo;). In cases following surgery involving the anterior segment (eg, cataract surgery) or following keratomycosis, the aqueous is usually involved first.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27883735\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In temperate climates, fungal endophthalmitis is usually endogenous and caused by Candida spp [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/1\">",
"     1",
"    </a>",
"    ]. In a review of 51 patients with endogenous fungal endophthalmitis in Florida, 75 percent were due to yeast (95 percent of which were Candida species) and only 25 percent were due to molds [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/2\">",
"     2",
"    </a>",
"    ]. In tropical regions, however, most cases of fungal endophthalmitis are due to molds and are usually exogenous in origin. Because Candida endophthalmitis and mold endophthalmitis typically have different epidemiology and presentation, we will discuss them separately below. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363859203\">",
"    <span class=\"h2\">",
"     Candida endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of Candida endophthalmitis are endogenous, but some cases are exogenous, resulting from ocular trauma, surgery, or extension of corneal infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2721592\">",
"    <span class=\"h3\">",
"     Endogenous Candida endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all cases of yeast endophthalmitis are caused by Candida species [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/2\">",
"     2",
"    </a>",
"    ]. Other yeasts, such as Cryptococcus, can also cause endogenous endophthalmitis, but these cases are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Although all species of Candida have been reported to cause endogenous endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/6\">",
"     6",
"    </a>",
"    ], the most common is C. albicans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/7\">",
"     7",
"    </a>",
"    ]. In a review that included 36 cases of endogenous Candida endophthalmitis, 33 (92 percent) were due to C. albicans, and the remainder were due to C. tropicalis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\", section on 'Prevalence of Candida species'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endogenous Candida endophthalmitis is a complication of candidemia and is seen most often in hospitalized patients, in whom a major risk factor is an indwelling central venous catheter. Other risk factors for hospital-acquired Candida endophthalmitis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    , broad-spectrum antibiotics, recent abdominal surgery, neutropenia, and glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/6,8-11\">",
"     6,8-11",
"    </a>",
"    ]. Risk factors for candidemia are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In hospitalized patients with candidemia, the overall prevalence of ocular involvement has varied from 2 to 26 percent, and the subset of cases with significant vitritis (endophthalmitis) has ranged from 0 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/7,11-15\">",
"     7,11-15",
"    </a>",
"    ]. Excluding nonspecific retinal lesions decreases the reported incidence of endophthalmitis, whereas performing repeated eye examinations of patients with candidemia who have a negative initial examination can increase the number of identified patients. Large prospective trials comparing various antifungal agents for candidemia have reported similar prevalence rates. In a trial that included 370 patients with candidemia, 40 patients (11 percent) had ocular involvement, 6 of whom (1.6 percent) had significant vitritis (endophthalmitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/7\">",
"     7",
"    </a>",
"    ]. An additional 20 patients had less specific findings but were thought to have possible ocular involvement. Of the total of 60 patients, 49 had findings consistent with ocular involvement at baseline, and an additional 11 patients developed ocular abnormalities during treatment. The duration of candidemia was slightly longer in patients with ocular involvement (median 4 days, range 1 to 18 days) compared with those without (median 3 days, range 1 to 26 days), a difference that was statistically significant.",
"   </p>",
"   <p>",
"    In outpatients who do not have a history of recent hospitalization or an indwelling central venous catheter, intravenous drug use is the major risk factor for endogenous Candida endophthalmitis. Over a seven-year period (2001 to 2007) at an eye and ear hospital in Australia, 19 of 27 patients (70 percent) presenting with endogenous fungal endophthalmitis were intravenous drug users [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/16\">",
"     16",
"    </a>",
"    ]. Of these 19 patients, 13 had positive intraocular cultures and all grew Candida species (C. albicans in seven, C. dubliniensis in four, and C. tropicalis in two). The source of the Candida in such cases may be oral flora. In some cases in this series and others, the drug injected intravenously was sublingual or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    that had been diluted with water. The buprenorphine was being used to treat the drug addiction, and, in some cases, the user admitted to removing the partially dissolved tablet from his or her mouth prior to diluting and injecting it [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In other cases, oral flora may be introduced when the drug user licks the needle prior to intravenous injection. This practice appears to be common; one study from New York City found that one-third of the 40 interviewed drug users acknowledged licking their needle [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/19\">",
"     19",
"    </a>",
"    ]. An unusual source of Candida occurred in the 1980s, when there was a large outbreak of Candida endophthalmitis among injection drug users who used brown heroin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This type of heroin requires an acidic diluent, and the lemon juice used for this purpose was thought to be the major source of the Candida [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2726019\">",
"    <span class=\"h3\">",
"     Exogenous Candida endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous Candida endophthalmitis is rare. In a series of all patients treated for exogenous fungal endophthalmitis at an eye hospital in Florida over a 16-year period, Candida species accounted for only 6 of the 41 cases (15 percent), whereas molds caused 35 cases (85 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/23\">",
"     23",
"    </a>",
"    ]. Among the six Candida cases, three occurred after surgery (corneal transplant and intraocular lens [IOL] implant exchange in two, cataract surgery in one), two occurred after trauma, and one occurred as an extension of keratomycosis. The time from surgery or keratitis to the diagnosis of endophthalmitis was long (five weeks to six months), but very short in those cases due to trauma (one day). Some exogenous Candida endophthalmitis cases have followed corneal transplantation, in which donor-to-host transmission occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. These patients presented with endophthalmitis acutely (ie, one day) following the corneal transplant.",
"   </p>",
"   <p>",
"    In a series of 113 patients with fungal endophthalmitis in India, 90 percent of cases were exogenous, caused either by surgery (53 patients) or trauma (48 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/26\">",
"     26",
"    </a>",
"    ]. As in the series from Florida, the majority of the exogenous cases were due to molds. Twelve (23 percent) of the 52 culture-positive exogenous cases were due to Candida spp, and 75 percent followed eye surgery, including cataract surgery. C. tropicalis (five cases) and C. albicans (four cases) were the most common species.",
"   </p>",
"   <p>",
"    All species of Candida have been described as causing exogenous endophthalmitis, but C. parapsilosis has been commonly reported in post-surgical outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The most likely reason for this is that C. parapsilosis has a high propensity to survive in irrigation fluids and prosthetic materials [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/30\">",
"     30",
"    </a>",
"    ]. The largest reported outbreak of C. parapsilosis endophthalmitis, involving 13 patients, was traced to an ophthalmic irrigating solution that was contaminated during the manufacturing process and was used during IOL implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2726026\">",
"    <span class=\"h2\">",
"     Mold endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mold endophthalmitis is rare in the United States except in hot, humid regions, such as Florida, where molds account for 6 percent of all culture-positive endophthalmitis cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/31\">",
"     31",
"    </a>",
"    ]. Mold endophthalmitis is much more common in India and other hot, humid countries. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2726120\">",
"    <span class=\"h3\">",
"     Endogenous mold endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endogenous mold endophthalmitis occurs rarely and is usually associated with intravenous drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/32,33\">",
"     32,33",
"    </a>",
"    ] or immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/34\">",
"     34",
"    </a>",
"    ]. A review of 86 cases of endogenous Aspergillus endophthalmitis published in the English language literature from 1949 to 2001 noted that 27 percent occurred in intravenous drug users, 23 percent in solid organ transplant recipients, 17 percent in patients with chronic lung disease, and 43 percent in patients who had been treated with glucocorticoids previously [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/35\">",
"     35",
"    </a>",
"    ]. The predominant species was Aspergillus fumigatus, but A. flavus also occurred commonly and was strongly linked to intravenous drug use.",
"   </p>",
"   <p>",
"    In a retrospective study at a cancer center in Texas between 1991 and 2007, among 15 patients with mold endophthalmitis, all had underlying hematologic malignancies and over one-half had undergone hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/34\">",
"     34",
"    </a>",
"    ]. Fusarium spp (five cases), Aspergillus spp (four), and Scedosporium spp (four) caused 87 percent of cases; the remaining two cases were caused by Mucor spp and Rhizomucor spp.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522538044\">",
"    <span class=\"h3\">",
"     Exogenous mold endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mold endophthalmitis is usually exogenous, occurring as a result of extension of keratomycosis, eye surgery, or penetrating ocular trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/23\">",
"     23",
"    </a>",
"    ]. In a series of exogenous fungal endophthalmitis cases seen at an eye hospital in Florida over 16 years, keratitis accounted for nearly one-half of the 35 cases of mold endophthalmitis (17 cases), whereas eye surgery (10 cases) and eye trauma (8 cases) each accounted for approximately 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/23\">",
"     23",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In cases that occur as an extension of fungal keratitis, the aqueous humor is nearly always involved first. The microbiology reflects that of keratomycosis, with Fusarium and Aspergillus spp being the most common etiologies. In the Florida study, 13 of 17 keratitis-related mold endophthalmitis cases were due to Fusarium spp, with 4 occurring between 2004 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/23\">",
"     23",
"    </a>",
"    ]. Some of these cases may reflect the international outbreak of Fusarium keratitis (over 250 cases) that occurred between 2004 and 2006. This outbreak was linked to the use of a specific lens solution and poor contact lens care; one report of a subset of patients from this outbreak noted that 6 percent of patients developed endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=see_link&amp;anchor=H773301007#H773301007\">",
"     \"Clinical manifestations and diagnosis of Fusarium infection\", section on 'Keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States and Europe, mold endophthalmitis is rare after eye surgery. When it does occur, it usually presents subacutely rather than acutely, in contrast with most cases of bacterial postoperative endophthalmitis. Two large series of acute (&lt;6 weeks) post-cataract endophthalmitis in Florida and France, totaling 173 cases, reported that all cases were due to bacteria: there were no cases of acute fungal endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The onset of symptoms and diagnosis are often delayed: in one review that included 10 cases of postoperative exogenous mold endophthalmitis, 60 percent presented two months or more after eye surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In tropical regions of the world, postoperative mold endophthalmitis is more common, and may present more acutely. In two retrospective reviews of the microbiology of postoperative endophthalmitis in India, molds caused 22 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In a series from India of 27 post-cataract fungal endophthalmitis cases (22 with mold endophthalmitis), over 80 percent presented within four weeks of surgery. Aspergillus was the major etiology in this series and in others.",
"   </p>",
"   <p>",
"    Some post-surgical endophthalmitis cases have occurred in the setting of nosocomial outbreaks, as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An outbreak of fungal endophthalmitis was detected in 33 patients in seven states in the United States in 2012 and was linked to Brilliant Blue dye and triamcinolone-containing products used during vitrectomies; the contaminated products were prepared in a single compounding pharmacy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/42\">",
"       42",
"      </a>",
"      ]. The dye was associated with Fusarium spp infection, whereas the triamcinolone-containing products were associated with Bipolaris spp infection.",
"     </li>",
"     <li>",
"      An outbreak of Aspergillus endophthalmitis occurred in five patients who had undergone cataract surgery 4 to 15 days earlier during a period of construction at a hospital in Saudi Arabia [",
"      <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An outbreak of Fusarium endophthalmitis occurred in nine patients who underwent cataract surgery on a single day in the same operating room in a hospital in Turkey [",
"      <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/44\">",
"       44",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       Cefuroxime",
"      </a>",
"      from the same vial was injected intracamerally in all patients at the end of surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27883756\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2721615\">",
"    <span class=\"h2\">",
"     Endogenous endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on experimental studies of endogenous Candida endophthalmitis in rabbits, it is apparent that Candida spp gain entrance to the eye by first seeding the highly vascular choroid (",
"    <a class=\"graphic graphic_figure graphicRef57690 \" href=\"UTD.htm?41/35/42549\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/45\">",
"     45",
"    </a>",
"    ]. There the yeasts proliferate and invoke focal inflammation, then extend to the vitreous body, causing further inflammation.",
"   </p>",
"   <p>",
"    In a study of experimentally induced endogenous Aspergillus endophthalmitis in 14 rabbits, one-half of which were immunosuppressed, the location of infection varied by duration of survival after fungemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/46\">",
"     46",
"    </a>",
"    ]. In rabbits that survived less than two weeks after fungemia, ocular fungal infection was localized primarily in the choroid, whether or not the animals were immunosuppressed. Large choroidal abscesses were seen in some of the immunosuppressed rabbits, and serous detachments were common in both groups. In immunocompetent and immunosuppressed rabbits surviving more than two weeks, the fungi were located in granulomas or &ldquo;fluff balls&rdquo; in the vitreous, but were not seen in the choroid or retina.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2726256\">",
"    <span class=\"h2\">",
"     Exogenous endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of exogenous endophthalmitis is inoculation of the aqueous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitreous with fungal species. Usually the aqueous is involved first, since most cases follow anterior eye surgery (eg, cataract surgery, corneal transplantation) or eye trauma (",
"    <a class=\"graphic graphic_figure graphicRef57690 \" href=\"UTD.htm?41/35/42549\">",
"     figure 1",
"    </a>",
"    ). The infection may progress posteriorly to involve the vitreous, especially if the posterior lens capsule was ruptured during surgery or trauma. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27883763\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial symptoms in fungal endophthalmitis may be floaters and a subtle decrease in vision. Progressive loss of vision in the affected eye usually prompts the patient to seek medical attention. Eye pain may be minimal or absent until late in the course. Unless there is concomitant systemic fungal infection, patients do not have fever, chills, or leukocytosis.",
"   </p>",
"   <p>",
"    Endophthalmitis is suspected clinically based upon the patient&rsquo;s presenting complaints, risk factors (eg, recent indwelling central catheter or intravenous drug use for endogenous endophthalmitis, eye trauma, or surgery for exogenous endophthalmitis), and the ophthalmic examination. (See",
"    <a class=\"local\" href=\"#H79280403\">",
"     'Ophthalmic examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535100592\">",
"    <span class=\"h2\">",
"     Endogenous fungal endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of patients have unilateral eye involvement, both eyes can be affected. Symptoms of vision loss may develop days to weeks after the fungemia. There is often minimal pain until the infection is advanced.",
"   </p>",
"   <p>",
"    If the eye was seeded by transient fungemia that infected no other organs, the patient may be systemically well at the time of presentation with eye symptoms, have a normal white blood count, and have negative blood cultures. This is often the case in outpatients with endogenous yeast or mold endophthalmitis due to intravenous drug use. Similarly, candidemia may be transient in patients with indwelling central venous catheters in which the organism seeds the eye but no other organs. Such patients have no evidence of systemic Candida infection at the time of presentation with eye symptoms, and the diagnosis of Candida endophthalmitis may be delayed. In a retrospective review of 15 patients with endogenous Candida endophthalmitis, 11 of whom had had an indwelling venous catheter, the average time from symptom onset to treatment was two months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/47\">",
"     47",
"    </a>",
"    ]. In patients with risk factors for transient fungemia (eg, intravenous drug use, recent indwelling central venous catheter), endogenous fungal endophthalmitis should be considered in the differential diagnosis of patients presenting with posterior uveitis or panuveitis.",
"   </p>",
"   <p>",
"    In contrast, hospitalized patients who develop endogenous fungal endophthalmitis are typically very ill. They may have candidemia from indwelling central venous catheters, or have fungemia related to immunosuppression. The eye infection is often clinically silent at first, and, in addition, hospitalized patients with fungemia may be too ill to complain of their symptoms. As a consequence, endophthalmitis may be missed unless patients with fungemia are examined by an ophthalmologist.",
"   </p>",
"   <p>",
"    In an autopsy study of 85 orthotopic liver transplant recipients, Aspergillus endophthalmitis was noted in six patients (7 percent), only one of whom was diagnosed with endophthalmitis before death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/48\">",
"     48",
"    </a>",
"    ]. Fourteen patients (17 percent) had invasive pulmonary aspergillosis and 10 (12 percent) had disseminated disease. The eyes were the second most common site of infection. Two patients had eye involvement as the only nonpulmonary site of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535100623\">",
"    <span class=\"h2\">",
"     Exogenous fungal endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with exogenous fungal endophthalmitis, the onset of symptoms occurs after a variable period of time. A large series from India found that the average time to presentation was 7 days in 48 posttraumatic fungal endophthalmitis cases and 20 days in 53 postoperative cases, although a significant percentage presented within 48 hours (46 and 21 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/26\">",
"     26",
"    </a>",
"    ]. Only 2 percent of posttraumatic cases, but 11 percent of postoperative cases presented more than four weeks after trauma or surgery.",
"   </p>",
"   <p>",
"    In a series from Florida, 10 patients with posttraumatic fungal endophthalmitis developed symptoms an average of 1.8 months after trauma (range one day to six months), and 18 patients with keratomycosis developed endophthalmitis four days to six months after the initial corneal ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79280403\">",
"    <span class=\"h1\">",
"     OPHTHALMIC EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ophthalmic examination reflects the endogenous or exogenous origin of infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In endogenous endophthalmitis, the cornea is usually normal and there may be minimal inflammation in the anterior segment of the eye. Initially, the findings may be primarily in the posterior segment of the eye.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In endogenous Candida endophthalmitis, chorioretinitis may be the only finding initially. The classic findings of chorioretinal involvement are focal, white, infiltrative, often mound-like lesions on the retina (",
"      <a class=\"graphic graphic_picture graphicRef58685 \" href=\"UTD.htm?25/1/25630\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef73575 \" href=\"UTD.htm?26/20/26959\">",
"       picture 2",
"      </a>",
"      ). When vitreous extension occurs, a vitreal haze is present (",
"      <a class=\"graphic graphic_picture graphicRef52795 \" href=\"UTD.htm?8/59/9151\">",
"       picture 3",
"      </a>",
"      ); sometimes, fluffy white balls or \"snowballs\" or a &ldquo;string of pearls&rdquo; in the vitreous are noted (",
"      <a class=\"graphic graphic_picture graphicRef73318 \" href=\"UTD.htm?24/39/25214\">",
"       picture 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/8,9,11\">",
"       8,9,11",
"      </a>",
"      ]. The degree of vitreous inflammation is graded on a 0 to 4 scale. Inflammation may also extend to the aqueous, where the same scale of inflammation applies. With marked inflammation, the white blood cells in the aqueous may settle out in the bottom as a hypopyon (",
"      <a class=\"graphic graphic_picture graphicRef59911 \" href=\"UTD.htm?1/45/1745\">",
"       picture 5",
"      </a>",
"      ) or form an inflammatory membrane within the anterior chamber.",
"     </li>",
"     <li>",
"      In endogenous mold endophthalmitis, the initial infection may appear as a choroidal or subretinal mass, or as white lesions in the posterior vitreous. There may be significant vitritis, and typically there are clumps or &ldquo;fluff balls&rdquo; rather than a diffuse, homogenous vitritis. Inflammation may extend to the aqueous. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In exogenous fungal endophthalmitis due to trauma, the initial surface injury may be apparent. The intraocular inflammation may have a clumped rather than diffuse appearance (",
"      <a class=\"graphic graphic_picture graphicRef60487 \" href=\"UTD.htm?29/45/30418\">",
"       picture 6",
"      </a>",
"      ). In postoperative fungal endophthalmitis, there may be white blood cells and &ldquo;flare&rdquo; (protein) in the anterior chamber and keratitic precipitates (clumps of white blood cells) on the corneal endothelium and anterior surface of the lens implant, if present [",
"      <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/27\">",
"       27",
"      </a>",
"      ]. A hypopyon may be present (",
"      <a class=\"graphic graphic_picture graphicRef59911 \" href=\"UTD.htm?1/45/1745\">",
"       picture 5",
"      </a>",
"      ). If extension to the vitreous has occurred, there may be vitritis. The view of the retina may be obscured by the intraocular inflammation. In cases of exogenous mold endophthalmitis that occur as an extension of corneal infection (keratomycosis), slit lamp examination will demonstrate the corneal infiltrate and also may reveal filamentous strands extending into the aqueous from the back of the involved cornea. There may be a hypopyon (",
"      <a class=\"graphic graphic_picture graphicRef59911 \" href=\"UTD.htm?1/45/1745\">",
"       picture 5",
"      </a>",
"      ), and in some cases, there may be a dense, white, clumped material in the anterior chamber.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27883777\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1866834\">",
"    <span class=\"h2\">",
"     Approach to diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endophthalmitis is suspected clinically based on the patient&rsquo;s presenting complaints, risk factors for fungal endophthalmitis (eg, intravenous drug use, recent indwelling central venous catheter), and the ophthalmic examination (see",
"    <a class=\"local\" href=\"#H27883763\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H79280403\">",
"     'Ophthalmic examination'",
"    </a>",
"    above). In order to save sight, patients with candidemia should undergo an ophthalmic examination as soon as possible to detect possible ocular infection. The 2009 Infectious Diseases Society of America guidelines for the treatment of candidiasis recommend that all patients in whom candidemia is documented should have a dilated retinal examination, preferably by an ophthalmologist [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/49\">",
"     49",
"    </a>",
"    ]. In a 2007 review of 100 patients with candidemia, only 80 underwent an ophthalmic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/12\">",
"     12",
"    </a>",
"    ]. Ophthalmic examination was much more likely to occur when an infectious diseases consultation was obtained (89 versus 54 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood cultures should be obtained from",
"    <strong>",
"     all",
"    </strong>",
"    patients with suspected endogenous endophthalmitis. However, negative blood cultures do not exclude a diagnosis of fungal endophthalmitis, since seeding of the eye may have occurred during transient fungemia. (See",
"    <a class=\"local\" href=\"#H27883806\">",
"     'Blood cultures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    To establish the diagnosis of fungal endophthalmitis, samples of the vitreous",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    aqueous, if primarily involved) may be obtained by an ophthalmologist and submitted for stains and cultures. Such sampling is especially important for diagnosis in patients who present with acute or subacute intraocular inflammation of unknown etiology and who have eye findings consistent with fungal endophthalmitis, but in whom blood cultures are negative. Obtaining intraocular samples may not be necessary for diagnosis in other cases of fungal endophthalmitis, such as in patients with documented candidemia and funduscopic findings typical of Candida chorioretinitis, or in patients with keratomycosis of known fungal etiology whose infection has extended into the aqueous.",
"   </p>",
"   <p>",
"    Any time the vitreous (or aqueous) is sampled, material should be sent for stains and cultures. In patients in whom the diagnosis of fungal endophthalmitis is suspected, but not established, the vitreous (and aqueous, if involved) should be sampled. Vitreous samples are obtained either by needle aspiration or vitrectomy (",
"    <a class=\"graphic graphic_figure graphicRef59512 \" href=\"UTD.htm?30/11/30899\">",
"     figure 2",
"    </a>",
"    ). Vitrectomy has a higher yield than needle aspiration of the vitreous [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/1\">",
"     1",
"    </a>",
"    ]. Aqueous samples are obtained by needle aspiration, or are obtained intraoperatively in cases of keratomycosis requiring corneal transplantation. In keratomycosis cases, samples of the removed cornea should be sent for fungal stain and culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2937?source=see_link&amp;anchor=H365246849#H365246849\">",
"     \"Treatment of endophthalmitis due to molds\", section on 'Vitrectomy and removal of foreign bodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27883799\">",
"    <span class=\"h2\">",
"     Microbiology studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraocular samples should be sent for fungal stain and culture, as well as Gram stain and bacterial culture since it is sometimes not possible to differentiate fungal from bacterial infections based on clinical appearance alone. Fungal cultures should be specifically requested, since molds typically grow best on Sabouraud&rsquo;s dextrose agar and at a lower incubation temperature (25&deg;C) than used for bacterial cultures. Stains of intraocular fluids should also be requested. Gram stain identifies yeast but frequently cannot visualize the hyphae of molds. A fungal stain, such as calcofluor white, shows fluorescence of the cell wall of yeasts and molds and should always be requested. &nbsp;",
"   </p>",
"   <p>",
"    If a vitrectomy has been performed, the vitreous washings should be filtered through a Millipore filter and the filter paper sterilely divided and incubated on various media. The ophthalmologist will also usually obtain a vitreous &ldquo;biopsy&rdquo; of undiluted vitreous at the start of the operation, and this material should be stained and cultured as well. Vitrectomy is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=see_link&amp;anchor=H278914238#H278914238\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\", section on 'Intravitreal antifungal agents and vitrectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27883806\">",
"    <span class=\"h2\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to an ophthalmic examination and sampling of the vitreous for stains and cultures, blood cultures should be obtained from",
"    <strong>",
"     all",
"    </strong>",
"    patients with suspected endogenous endophthalmitis. It is important to note that negative blood cultures do not exclude endogenous fungal endophthalmitis, because the eye may have been seeded much earlier during transient fungemia. This is the typical situation in asymptomatic patients who present with Candida endophthalmitis days to weeks after removal of an indwelling central catheter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\", section on 'Blood cultures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1866771\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular techniques, such as the polymerase chain reaction (PCR), have been used on intraocular fluids to diagnose mold endophthalmitis. The sensitivity and specificity are not yet known. In one study from India, routine stains and cultures were compared with PCR on intraocular fluid samples (48 vitreous, 2 aqueous) from 50 patients suspected of having postoperative fungal endophthalmitis and 25 uninfected control patients undergoing vitrectomy for another reason [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13849/abstract/50\">",
"     50",
"    </a>",
"    ]. Four of the samples from patients suspected of having postoperative fungal endophthalmitis were positive for fungi by calcofluor white stain (three for hyphae and one for yeast), and of these, two grew molds; PCR was positive in three cases that were positive for hyphae by calcofluor white stain. PCR was positive in an additional three cases that were negative by stain and culture. None of the control patients had a positive culture or PCR result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48201985\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term \"endophthalmitis\" means infection within the eye involving the vitreous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aqueous (",
"      <a class=\"graphic graphic_figure graphicRef57690 \" href=\"UTD.htm?41/35/42549\">",
"       figure 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Endogenous fungal endophthalmitis results from fungal seeding of the eye via the bloodstream. In most cases of endogenous endophthalmitis, the highly vascular choroid is seeded first. &nbsp;",
"     </li>",
"     <li>",
"      Exogenous fungal endophthalmitis means that the infection was introduced from the &ldquo;outside,&rdquo; either by eye surgery, eye trauma, or extension of fungal infection of the cornea (termed &ldquo;fungal keratitis&rdquo; or &ldquo;keratomycosis&rdquo;). In cases following surgery involving the anterior segment (eg, cataract surgery) or following keratomycosis, the aqueous is typically infected first. (See",
"      <a class=\"local\" href=\"#H27883231\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In temperate climates, endophthalmitis is most commonly caused by Candida spp, and is typically endogenous in origin (ie, in the setting of candidemia). In contrast, in tropical climates, mold endophthalmitis is more common than Candida endophthalmitis. Mold endophthalmitis is usually exogenous in origin. (See",
"      <a class=\"local\" href=\"#H27883735\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The onset of symptoms in endogenous fungal endophthalmitis may occur subacutely, days to several weeks after fungemia. Initially, endogenous fungal endophthalmitis may be associated with minimal eye pain, and vision decrease may be subtle until the infection is advanced. In patients with risk factors for transient fungemia (eg, intravenous drug use, recent indwelling central venous catheter), endogenous fungal endophthalmitis should be considered in the differential diagnosis of patients presenting with posterior uveitis or panuveitis. (See",
"      <a class=\"local\" href=\"#H535100592\">",
"       'Endogenous fungal endophthalmitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that",
"      <strong>",
"       all",
"      </strong>",
"      patients with candidemia undergo an ophthalmic examination by an ophthalmologist as soon as possible to detect possible ocular infection. Early findings of endogenous Candida endophthalmitis include fluffy, white lesions in the choroid and retina (chorioretinitis), often with overlying vitreous inflammation (",
"      <a class=\"graphic graphic_picture graphicRef58685 \" href=\"UTD.htm?25/1/25630\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef73575 \" href=\"UTD.htm?26/20/26959\">",
"       picture 2",
"      </a>",
"      ). Marked vitritis characterizes advanced Candida endophthalmitis (",
"      <a class=\"graphic graphic_picture graphicRef52795 \" href=\"UTD.htm?8/59/9151\">",
"       picture 3",
"      </a>",
"      ), and the vitreous inflammation often has a clumped appearance, described as &ldquo;fluff balls&rdquo; or &ldquo;string of pearls&rdquo; (",
"      <a class=\"graphic graphic_picture graphicRef73318 \" href=\"UTD.htm?24/39/25214\">",
"       picture 4",
"      </a>",
"      ). Endogenous mold endophthalmitis often has a similar appearance, with discrete white infiltrates in the choroid and retina and dense infiltrates (&ldquo;fluff balls&rdquo;) in the vitreous. The intraocular inflammation in exogenous mold endophthalmitis may also have a clumped appearance (",
"      <a class=\"graphic graphic_picture graphicRef60487 \" href=\"UTD.htm?29/45/30418\">",
"       picture 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H79280403\">",
"       'Ophthalmic examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fungal endophthalmitis is suspected clinically based upon the patient&rsquo;s presenting complaints, risk factors for fungal endophthalmitis (eg, intravenous drug use, indwelling central venous catheter, severe immunocompromise, recent eye trauma or eye surgery) and the ophthalmic examination. Blood cultures should be obtained from",
"      <strong>",
"       all",
"      </strong>",
"      patients with suspected endogenous endophthalmitis. Negative blood cultures do not exclude a diagnosis of fungal endophthalmitis, since seeding of the eye may have occurred during transient fungemia. (See",
"      <a class=\"local\" href=\"#H1866834\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To establish the diagnosis of fungal endophthalmitis, samples of the vitreous",
"      <span class=\"nowrap\">",
"       (and/or",
"      </span>",
"      aqueous, if primarily involved) may be obtained by an ophthalmologist and submitted for stains and cultures. Such sampling is especially important for diagnosis in patients who present with acute or subacute intraocular inflammation of unknown etiology and who have eye findings consistent with fungal endophthalmitis, but in whom blood cultures are negative. Obtaining intraocular samples may not be necessary for diagnosis in other cases of fungal endophthalmitis, such as in patients with documented candidemia and funduscopic findings typical of Candida chorioretinitis, or in patients with keratomycosis of known fungal etiology whose infection has extended into the aqueous. (See",
"      <a class=\"local\" href=\"#H1866834\">",
"       'Approach to diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27883799\">",
"       'Microbiology studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Durand ML. Endophthalmitis. In: Principles and Practice of Infectious Diseases, 7th edition, Mandell GL, Bennett JE, Dolin R.  (Eds), Churchill Livingstone Elsevier, Philadelphia 2010. Vol 1, p.1553.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/2\">",
"      Lingappan A, Wykoff CC, Albini TA, et al. Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes. Am J Ophthalmol 2012; 153:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/3\">",
"      Sheu SJ, Chen YC, Kuo NW, et al. Endogenous cryptococcal endophthalmitis. Ophthalmology 1998; 105:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/4\">",
"      Cunningham ET Jr, Seiff SR, Berger TG, et al. Intraocular coccidioidomycosis diagnosed by skin biopsy. Arch Ophthalmol 1998; 116:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/5\">",
"      Gonzales CA, Scott IU, Chaudhry NA, et al. Endogenous endophthalmitis caused by Histoplasma capsulatum var. capsulatum: a case report and literature review. Ophthalmology 2000; 107:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/6\">",
"      Joshi N, Hamory BH. Endophthalmitis caused by non-albicans species of Candida. Rev Infect Dis 1991; 13:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/7\">",
"      Oude Lashof AM, Rothova A, Sobel JD, et al. Ocular manifestations of candidemia. Clin Infect Dis 2011; 53:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/8\">",
"      Griffin JR, Pettit TH, Fishman LS, Foos RY. Blood-borne Candida endophthalmitis. A clinical and pathologic study of 21 cases. Arch Ophthalmol 1973; 89:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/9\">",
"      Edwards JE Jr, Foos RY, Montgomerie JZ, Guze LB. Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine (Baltimore) 1974; 53:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/10\">",
"      Henderson DK, Edwards JE Jr, Montgomerie JZ. Hematogenous candida endophthalmitis in patients receiving parenteral hyperalimentation fluids. J Infect Dis 1981; 143:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/11\">",
"      Donahue SP, Greven CM, Zuravleff JJ, et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology 1994; 101:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/12\">",
"      Popovich, K, Malani, PN, Kauffman, CA, et al. Compliance with Infectious Diseases Society of America guidelines for ophthalmologic evaluation of patients with candidemia. Infect Dis Clin Pract 2007; 15:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/13\">",
"      Krishna R, Amuh D, Lowder CY, et al. Should all patients with candidaemia have an ophthalmic examination to rule out ocular candidiasis? Eye (Lond) 2000; 14 ( Pt 1):30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/14\">",
"      Kannangara S, Shindler D, Kunimoto DY, et al. Candidemia complicated by endophthalmitis: a prospective analysis. Eur J Clin Microbiol Infect Dis 2007; 26:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/15\">",
"      Rodr&iacute;guez-Adri&aacute;n LJ, King RT, Tamayo-Derat LG, et al. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine (Baltimore) 2003; 82:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/16\">",
"      Connell PP, O'Neill EC, Amirul Islam FM, et al. Endogenous endophthalmitis associated with intravenous drug abuse: seven-year experience at a tertiary referral center. Retina 2010; 30:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/17\">",
"      Moratti E, Kashanpour H, Lombardelli T, Maisto M. Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy. Clin Drug Investig 2010; 30 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/18\">",
"      Aboltins CA, Allen P, Daffy JR. Fungal endophthalmitis in intravenous drug users injecting buprenorphine contaminated with oral Candida species. Med J Aust 2005; 182:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/19\">",
"      Deutscher M, Perlman DC. Why some injection drug users lick their needles: a preliminary survey. Int J Drug Policy 2008; 19:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/20\">",
"      Bisbe J, Miro JM, Latorre X, et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. Clin Infect Dis 1992; 15:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/21\">",
"      Mart&iacute;nez-V&aacute;zquez C, Fern&aacute;ndez-Ulloa J, Bord&oacute;n J, et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 1998; 27:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/22\">",
"      Newton-John HF, Wise K, Looke DF. Role of the lemon in disseminated candidiasis of heroin abusers. Med J Aust 1984; 140:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/23\">",
"      Wykoff CC, Flynn HW Jr, Miller D, et al. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology 2008; 115:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/24\">",
"      Merchant A, Zacks CM, Wilhelmus K, et al. Candidal endophthalmitis after keratoplasty. Cornea 2001; 20:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/25\">",
"      Tappeiner C, Goldblum D, Zimmerli S, et al. Donor-to-host transmission of Candida glabrata to both recipients of corneal transplants from the same donor. Cornea 2009; 28:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/26\">",
"      Chakrabarti A, Shivaprakash MR, Singh R, et al. Fungal endophthalmitis: fourteen years' experience from a center in India. Retina 2008; 28:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/27\">",
"      Stern WH, Tamura E, Jacobs RA, et al. Epidemic postsurgical Candida parapsilosis endophthalmitis. Clinical findings and management of 15 consecutive cases. Ophthalmology 1985; 92:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/28\">",
"      McCray E, Rampell N, Solomon SL, et al. Outbreak of Candida parapsilosis endophthalmitis after cataract extraction and intraocular lens implantation. J Clin Microbiol 1986; 24:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/29\">",
"      Kauffman CA, Bradley SF, Vine AK. Candida endophthalmitis associated with intraocular lens implantation: efficacy of fluconazole therapy. Mycoses 1993; 36:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/30\">",
"      Weems JJ Jr. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992; 14:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/31\">",
"      Benz MS, Scott IU, Flynn HW Jr, et al. Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am J Ophthalmol 2004; 137:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/32\">",
"      Weishaar PD, Flynn HW Jr, Murray TG, et al. Endogenous Aspergillus endophthalmitis. Clinical features and treatment outcomes. Ophthalmology 1998; 105:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/33\">",
"      Young LH, Bazari H, Durand ML, Branda JA. Case records of the Massachusetts General Hospital. Case 33-2010. A 22-year-old woman with blurred vision and renal failure. N Engl J Med 2010; 363:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/34\">",
"      Lamaris GA, Esmaeli B, Chamilos G, et al. Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases. Eur J Clin Microbiol Infect Dis 2008; 27:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/35\">",
"      Riddell Iv J, McNeil SA, Johnson TM, et al. Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature. Medicine (Baltimore) 2002; 81:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/36\">",
"      Epstein AB. In the aftermath of the Fusarium keratitis outbreak: What have we learned? Clin Ophthalmol 2007; 1:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/37\">",
"      Rosenberg KD, Flynn HW Jr, Alfonso EC, Miller D. Fusarium endophthalmitis following keratitis associated with contact lenses. Ophthalmic Surg Lasers Imaging 2006; 37:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/38\">",
"      Cornut PL, Thuret G, Creuzot-Garcher C, et al. Relationship between baseline clinical data and microbiologic spectrum in 100 patients with acute postcataract endophthalmitis. Retina 2012; 32:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/39\">",
"      Lalwani GA, Flynn HW Jr, Scott IU, et al. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology 2008; 115:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/40\">",
"      Gupta A, Gupta V, Gupta A, et al. Spectrum and clinical profile of post cataract surgery endophthalmitis in north India. Indian J Ophthalmol 2003; 51:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/41\">",
"      Anand AR, Therese KL, Madhavan HN. Spectrum of aetiological agents of postoperative endophthalmitis and antibiotic susceptibility of bacterial isolates. Indian J Ophthalmol 2000; 48:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/42\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: Multistate outbreak of postprocedural fungal endophthalmitis associated with a single compounding pharmacy - United States, March-April 2012. MMWR Morb Mortal Wkly Rep 2012; 61:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/43\">",
"      Tabbara KF, al Jabarti AL. Hospital construction-associated outbreak of ocular aspergillosis after cataract surgery. Ophthalmology 1998; 105:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/44\">",
"      G&uuml;ngel H, Eren MH, P��narc�� EY, et al. An outbreak of Fusarium solani endophthalmitis after cataract surgery in an eye training and research hospital in Istanbul. Mycoses 2011; 54:e767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/45\">",
"      Omuta J, Uchida K, Yamaguchi H, Shibuya K. Histopathological study on experimental endophthalmitis induced by bloodstream infection with Candida albicans. Jpn J Infect Dis 2007; 60:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/46\">",
"      Aziz AA, Bullock JD, McGuire TW, et al. Aspergillus endophthalmitis: a clinical and experimental study. Trans Am Ophthalmol Soc 1992; 90:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/47\">",
"      Essman TF, Flynn HW Jr, Smiddy WE, et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1997; 28:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/48\">",
"      Hunt KE, Glasgow BJ. Aspergillus endophthalmitis. An unrecognized endemic disease in orthotopic liver transplantation. Ophthalmology 1996; 103:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/49\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13849/abstract/50\">",
"      Tarai B, Gupta A, Ray P, et al. Polymerase chain reaction for early diagnosis of post-operative fungal endophthalmitis. Indian J Med Res 2006; 123:671.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16953 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-211.167.112.14-E421669322-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13849=[""].join("\n");
var outline_f13_33_13849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48201985\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27883216\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27883231\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79279574\">",
"      Endogenous fungal endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79279581\">",
"      Exogenous fungal endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27883735\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H363859203\">",
"      Candida endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2721592\">",
"      - Endogenous Candida endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2726019\">",
"      - Exogenous Candida endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2726026\">",
"      Mold endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2726120\">",
"      - Endogenous mold endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H522538044\">",
"      - Exogenous mold endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27883756\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2721615\">",
"      Endogenous endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2726256\">",
"      Exogenous endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27883763\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H535100592\">",
"      Endogenous fungal endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H535100623\">",
"      Exogenous fungal endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H79280403\">",
"      OPHTHALMIC EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27883777\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1866834\">",
"      Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27883799\">",
"      Microbiology studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27883806\">",
"      Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1866771\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48201985\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16953\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16953|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/35/42549\" title=\"figure 1\">",
"      Eye anatomy in cross section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/11/30899\" title=\"figure 2\">",
"      Vitreous aspirate vitrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16953|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/1/25630\" title=\"picture 1\">",
"      Candida endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/20/26959\" title=\"picture 2\">",
"      Endogenous Candida endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/59/9151\" title=\"picture 3\">",
"      Endogenous Candida endophthalmitis with vitritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/39/25214\" title=\"picture 4\">",
"      Vitritis in endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/45/1745\" title=\"picture 5\">",
"      Hypopyon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/45/30418\" title=\"picture 6\">",
"      Exogenous mold endophthalmitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=related_link\">",
"      Clinical manifestations and diagnosis of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=related_link\">",
"      Epidemiology and pathogenesis of candidemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=related_link\">",
"      Treatment of endogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2937?source=related_link\">",
"      Treatment of endophthalmitis due to molds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36102?source=related_link\">",
"      Treatment of exogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_33_13850="Advanced cardiac life support (ACLS) in adults";
var content_f13_33_13850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Advanced cardiac life support (ACLS) in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/33/13850/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13850/contributors\">",
"     Charles N Pozner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/33/13850/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13850/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13850/contributors\">",
"     Richard L Page, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/33/13850/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/33/13850/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/33/13850/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The field of resuscitation has been evolving for more than two centuries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/1\">",
"     1",
"    </a>",
"    ]. The Paris Academy of Science recommended mouth-to-mouth ventilation for drowning victims in 1740 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/2\">",
"     2",
"    </a>",
"    ]. In 1891, Dr. Friedrich Maass performed the first documented chest compressions on humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/3\">",
"     3",
"    </a>",
"    ]. The American Heart Association (AHA) formally endorsed cardiopulmonary resuscitation (CPR) in 1963, and by 1966, they had adopted standardized CPR guidelines for instruction to lay-rescuers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advanced cardiac life support (ACLS) guidelines have evolved over the past several decades based on a combination of scientific evidence of variable strength and expert consensus. The American Heart Association (AHA) developed the most recent ACLS guidelines in 2010 using the comprehensive review of resuscitation literature performed by the International Liaison Committee on Resuscitation (ILCOR) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Guidelines are reviewed continually, but are formally released every five years, and published in the journals Circulation and Resuscitation.",
"   </p>",
"   <p>",
"    This topic will discuss the management of cardiac arrhythmias in adults as described in the 2010 ACLS Guidelines. The evidence supporting these guidelines is presented separately, as are issues related to controversial treatments for cardiac arrest patients, basic life support (BLS), airway management, and post-cardiac arrest management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35448?source=see_link\">",
"     \"Therapies of uncertain benefit in basic and advanced cardiac life support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35274?source=see_link\">",
"     \"Post-cardiac arrest management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVIDENCE BASED GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the nature of resuscitation research, few randomized controlled trials have been completed in humans. Many of the recommendations in the American Heart Association&rsquo;s 2010 Guidelines for advanced cardiac life support (hereafter referred to as the 2010 ACLS Guidelines) are made based upon retrospective studies, animal studies, and expert consensus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/5\">",
"     5",
"    </a>",
"    ]. Guideline recommendations are classified according to the GRADE system [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/6\">",
"     6",
"    </a>",
"    ]. The evidence supporting the 2010 ACLS Guidelines is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Excellent basic life support and its importance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excellent cardiopulmonary resuscitation (CPR) and early defibrillation for treatable arrhythmias remain the cornerstones of basic and advanced cardiac life support (ACLS). Although the 2010 American Heart Association (AHA) Guidelines for ACLS (2010 ACLS Guidelines) suggest several revisions, including medications, electrical therapy, and monitoring, the emphasis on excellent CPR and its critical role in resuscitative efforts remains unchanged (",
"    <a class=\"graphic graphic_algorithm graphicRef55548 \" href=\"UTD.htm?28/15/28912\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef61966 \" href=\"UTD.htm?12/19/12598\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/5\">",
"     5",
"    </a>",
"    ]. We emphasize the term &ldquo;excellent CPR&rdquo; because anything short of this standard does not achieve adequate cerebral and coronary perfusion, thereby compromising a patient&rsquo;s chances for neurologically intact survival. CPR is discussed in detail separately; key principles in the performance of ACLS are summarized in the following table (",
"    <a class=\"graphic graphic_table graphicRef83671 \" href=\"UTD.htm?37/32/38411\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, clinicians frequently interrupted CPR to check for pulses, perform tracheal intubation, or obtain venous access. The 2010 ACLS Guidelines strongly recommend that every effort be made",
"    <strong>",
"     NOT",
"    </strong>",
"    to interrupt CPR; other less vital interventions (eg, tracheal intubation or administration of medications to treat arrhythmias) are made either while CPR is performed or during the briefest possible interruption. Interventions that cannot be performed while CPR is in progress (eg, defibrillation) should be performed during brief interruptions at two minute intervals (after the completion of a full cycle of CPR). &nbsp;",
"   </p>",
"   <p>",
"    Studies in both the in-hospital and prehospital settings demonstrate that chest compressions are often performed incorrectly, inconsistently, and with excessive interruption [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Chest compressions must be of sufficient depth (at least 5 cm, or 2 inches) and rate (at least 100 per minute), and allow for complete recoil of the chest between compressions, to be effective.",
"   </p>",
"   <p>",
"    A single biphasic defibrillation remains the recommended treatment for ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT). CPR should be performed until the defibrillator is ready for immediate discharge and resumed immediately after the shock is given, without pausing to recheck a pulse at that moment. Interruptions in CPR (eg, for subsequent attempts at defibrillation or pulse checks) should occur no more frequently than every two minutes, and for the shortest possible duration. Key elements in the performance of manual defibrillation are described in the following table (",
"    <a class=\"graphic graphic_table graphicRef83670 \" href=\"UTD.htm?5/37/5723\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients are often over-ventilated during resuscitations, which can compromise venous return resulting in reduced cardiac output and inadequate cerebral and cardiac perfusion. A 30 to 2 compression to ventilation ratio (one cycle) is recommended in patients without advanced airways. According to the 2010 ACLS Guidelines, asynchronous ventilations at 8 to 10 per minute are administered if an endotracheal tube or extraglottic airway is in place, while continuous chest compressions are performed simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/12\">",
"     12",
"    </a>",
"    ]. We believe that 6 to 8 ventilations per minute are sufficient in the low-flow state of cardiac resuscitation and help to prevent over-ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Resuscitation team management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The resuscitation of a sudden cardiac arrest (SCA), by its nature a low frequency, high acuity event, is often chaotic. A growing body of literature demonstrates that by employing the principles of Crisis Resource Management (CRM), adapted from the aviation industry and introduced into medical care by anesthesiologists, disorganization during resuscitation decreases and patient care improves [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Training in these principles to improve the quality of ACLS performed by healthcare clinicians is feasible and recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two principles provide the foundation for CRM: leadership and communication [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/15\">",
"     15",
"    </a>",
"    ]. Resuscitations usually involve a number of healthcare providers from different disciplines, sometimes from different areas of an institution, who may not have worked together previously. Under these circumstances, role clarity can be difficult to establish. In CRM, it is imperative that one person assumes the role of team leader [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/15\">",
"     15",
"    </a>",
"    ]. This person is responsible for the global management of the resuscitation, including: ensuring that all required tasks are carried out competently; incorporating new information and coordinating communication among all team members; developing and implementing management strategies that will maximize patient outcome; and reassessing performance throughout the resuscitation.",
"   </p>",
"   <p>",
"    The team leader should avoid performing technical procedures, as performance of a task inevitably shifts attention from the primary leadership responsibilities. In circumstances where staffing is limited (eg, small community hospital), the team leader may be required to perform certain critical procedures. In these situations, leadership may be temporarily transferred to another clinician or the team leader may be forced temporarily to perform both roles, although this compromises the ability to provide proficient leadership.",
"   </p>",
"   <p>",
"    In CRM, communication is organized to provide effective and efficient care. All pertinent communication goes through the team leader and the team leader shares important information with the team. When the team leader determines the need to perform a task, the request is directed to a specific team member, ideally by name. That team member verbally acknowledges the request and performs the task or, if unable to do so, informs the team leader that someone else should be assigned. Specific emphasis is placed on the assigned team member repeating back medication doses and defibrillator energy settings to the team leader. This \"closed-loop\" communication leads to a more orderly transfer of information and is the appropriate standard for all communication during resuscitations.",
"   </p>",
"   <p>",
"    Though most decisions emanate from the team leader, a good team leader enlists the collective wisdom and experience of the entire team as needed. Extraneous personnel not involved with patient care are asked to leave in order to reduce noise and to ensure that orders from the leader and feedback from the resuscitation team can be heard clearly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Initial management and ECG interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2010 ACLS Guidelines, circulation has taken a more prominent role in the initial management of cardiac arrest. The new &lsquo;mantra&rsquo; is: circulation, airway, breathing (C-A-B). Once unresponsiveness is recognized, resuscitation begins by addressing circulation (chest compressions), followed by airway opening, and then rescue breathing. The 2010 ACLS Guidelines emphasize the importance of excellently performed, uninterrupted chest compressions and early defibrillation. Rescue breathing is performed after the initiation of excellent chest compressions and definitive airway management may be delayed if there is adequate rescue breathing without an advanced airway in place. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Excellent basic life support and its importance'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link&amp;anchor=H2399946#H2399946\">",
"     \"Basic life support (BLS) in adults\", section on 'Recognition of cardiac arrest'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the non-cardiac arrest situation, the other initial interventions for ACLS include administering oxygen, establishing vascular access, placing the patient on a cardiac and oxygen saturation monitor, and obtaining an electrocardiogram (ECG) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/5\">",
"     5",
"    </a>",
"    ]. Unstable patients must receive immediate care, even when data are incomplete or presumptive (",
"    <a class=\"graphic graphic_algorithm graphicRef55548 \" href=\"UTD.htm?28/15/28912\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Stable patients require an assessment of their electrocardiogram in order to provide appropriate treatment consistent with ACLS guidelines. Although it is best to make a definitive interpretation of the ECG prior to making management decisions, the settings in which ACLS guidelines are commonly employed require a modified, empirical approach. Such an approach is guided by the following questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the rhythm fast or slow?",
"     </li>",
"     <li>",
"      Are the QRS complexes wide or narrow?",
"     </li>",
"     <li>",
"      Is the rhythm regular or irregular?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The answers to these questions often enable the clinician to make a provisional diagnosis and initiate appropriate therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4318336\">",
"    <span class=\"h1\">",
"     AIRWAY MANAGEMENT DURING ACLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilation is performed during CPR to maintain adequate oxygenation and to eliminate carbon dioxide, although this is less important. Nevertheless, during the first few minutes following sudden cardiac arrest (SCA), oxygen delivery to the brain is limited primarily by reduced blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Therefore, in adults, the performance of excellent chest compressions takes priority over ventilation during the initial period of basic life support. In settings with multiple rescuers or clinicians, ventilations and chest compressions are performed simultaneously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although research has yet to identify the preferred parameters for ventilation (eg, respiratory rate, tidal volume, inspired oxygen concentration), it is widely believed that a lower minute ventilation is needed for patients in cardiac arrest. Therefore, lower respiratory rates are used (the 2010 ACLS Guidelines recommend 8 to 10 breaths per minute with an advanced airway in place; we believe 6 to 8 breaths are adequate). In addition, we know that hyperventilation is harmful, as it leads to increased intrathoracic pressure, which decreases venous return and compromises cardiac output. Tidal volumes of approximately 600 mL delivered in a controlled fashion such that chest rise occurs over no more than one second is recommended in the 2010 ACLS Guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link&amp;anchor=H8#H8\">",
"     \"Basic life support (BLS) in adults\", section on 'Ventilations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Taking these principles into account, the 2010 ACLS Guidelines support the use of a bag-mask device or a blindly placed supraglottic airway for ventilation during the initial management of SCA, deferring placement of an endotracheal tube, unless intubation can be competently performed without interrupting chest compressions. The performance of bag-mask ventilation (BMV) is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A blindly inserted supraglottic airway (eg, laryngeal mask airway, Combitube&trade;, laryngeal tube) can be placed without interrupting chest compressions, provides adequate ventilation in most cases, and reduces the risk of aspiration compared to bag-mask ventilation. Therefore, clinicians may prefer to ventilate with a supraglottic device while CPR is ongoing, rather than performing tracheal intubation. Supraglottic airways and tracheal intubation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/55/25466?source=see_link&amp;anchor=H7#H7\">",
"     \"Devices for difficult emergency airway management in adults\", section on 'Extraglottic devices'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28906?source=see_link\">",
"     \"Direct laryngoscopy and tracheal intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advanced airway management using a supraglottic airway or tracheal intubation may not be the best approach for managing cardiac arrest patients in the prehospital setting. This view is supported by a prospective observational nationwide Japanese study involving 649,359 patients with sudden out-of-hospital cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/20\">",
"     20",
"    </a>",
"    ]. In this study, the rate of survival with a favorable neurologic outcome was significantly lower among those managed with advanced airway techniques compared with bag-mask ventilation (1.1 vs 2.9 percent; OR 0.38, 95% CI 0.36-0.39). Higher rates of survival with a favorable neurologic outcome persisted across all analyzed subgroups, including adjustments for initial rhythm, return of spontaneous circulation, bystander CPR, and additional treatments. Although this study has limitations due to its observational approach and was performed in a single country and so may not be generalizable to all settings, its size and consistent findings across all subgroup analyses support its conclusions.",
"   </p>",
"   <p>",
"    If advanced airway management is to be performed at all in prehospital cardiac arrest patients, it must be done by competent providers, require less than 10 seconds to complete without interruption of excellent chest compressions, and be used only after all other more essential resuscitative maneuvers have been initiated. Once performed, rescuers must avoid hyperventilation. In addition, unless adequate BMV cannot be performed, placement of an advanced airway should be attempted only during active chest compressions or deferred to the two minute interval (after a complete cycle of CPR) when defibrillation or patient reassessment is performed.",
"   </p>",
"   <p>",
"    The 2010 ACLS Guidelines include the following additional recommendations about airway management during the performance of ACLS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although evidence is lacking, it is reasonable to provide 100 percent oxygen during CPR. In patients who are successfully resuscitated, it is important to avoid hyperoxia while maintaining oxygen saturation above 94 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35274?source=see_link&amp;anchor=H733416#H733416\">",
"       \"Post-cardiac arrest management in adults\", section on 'Mechanical ventilation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cricoid pressure is controversial and is no longer routinely recommended during intubation. It may be useful for preventing gastric insufflation during bag-mask ventilation. These issues are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link&amp;anchor=H12#H12\">",
"       \"Rapid sequence intubation in adults\", section on 'Protection (cricoid pressure) and positioning'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oropharyngeal and nasopharyngeal airways can be useful adjuncts. We encourage their use when performing bag-mask ventilation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link&amp;anchor=H9#H9\">",
"       \"Basic airway management in adults\", section on 'Airway adjuncts'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Continuous waveform capnography (performed in addition to clinical assessment) is recommended for both confirming and monitoring correct tracheal tube placement, and for monitoring the quality of CPR and the return of spontaneous circulation. If waveform capnography is not available, a non-waveform CO2 detector may be used, in addition to clinical assessment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link&amp;anchor=H4#H4\">",
"       \"Carbon dioxide monitoring (capnography)\", section on 'Clinical applications for intubated patients'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SPECIFIC ARRHYTHMIAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3328729\">",
"    <span class=\"h2\">",
"     Sudden cardiac arrest",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Ventricular fibrillation and pulseless ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT) are nonperfusing rhythms emanating from the ventricles, for which early rhythm identification, defibrillation, and cardiopulmonary resuscitation (CPR) are the mainstays of treatment (",
"    <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef61966 \" href=\"UTD.htm?12/19/12598\">",
"     figure 1",
"    </a>",
"    ). Early defibrillation is the most critical action in the resuscitation effort, followed by the performance of excellent CPR. Manage potentially treatable underlying causes as appropriate (",
"    <a class=\"graphic graphic_table graphicRef52416 \" href=\"UTD.htm?17/18/17708\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Begin performing excellent chest compressions as soon as sudden cardiac arrest (SCA) is recognized and continue while the defibrillator is being attached. If a defibrillator is not immediately available, continue CPR until one is obtained. As soon as a defibrillator is available, attach it to the patient, charge it, assess the rhythm, and treat appropriately (eg, defibrillate VF or pulseless VT; continue CPR if asystole or PEA). Resume CPR immediately after any shock is given. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link&amp;anchor=H2#H2\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\", section on 'VF and pulseless VT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the case of a witnessed cardiac arrest, perform defibrillation as quickly as possible. Decreased time to defibrillation improves the likelihood of successful conversion to a perfusing rhythm and of patient survival.",
"   </p>",
"   <p>",
"    Biphasic defibrillators are recommended because of their increased efficacy at lower energy levels [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The 2010 ACLS Guidelines recommend that when employing a biphasic defibrillator clinicians use the initial dose of energy recommended by the manufacturer (120 to 200 J). If this dose is not known, the maximal dose may be used. We suggest a first defibrillation using 200 J with a biphasic defibrillator or 360 J with a monophasic defibrillator for VF or pulseless VT. It should be noted that many automated external defibrillators (AEDs) do not allow for adjustment of the shock output.",
"   </p>",
"   <p>",
"    The 2010 ACLS Guidelines recommend the resumption of CPR immediately after defibrillation without rechecking for a pulse. CPR should not be interrupted to assess the rhythm and additional shocks should be considered no more frequently than every two minutes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link&amp;anchor=H4#H4\">",
"     \"Basic life support (BLS) in adults\", section on 'Phases of resuscitation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link&amp;anchor=H10#H10\">",
"     \"Basic life support (BLS) in adults\", section on 'Defibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If VF or pulseless VT persists after at least one attempt at defibrillation and two minutes of CPR, give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    (1 mg IV every three to five minutes) while CPR is performed continuously. Vasopressin (40 units IV) may replace the first or second dose of epinephrine.",
"   </p>",
"   <p>",
"    Although some study results have raised doubts about the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , including a large prospective observational study published in 2012, pending more conclusive data or a formal change in ACLS protocols, we suggest giving epinephrine in accordance with the existing Guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link&amp;anchor=H6#H6\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\", section on 'VF or VT arrest and vasopressors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence suggests that antiarrhythmic drugs provide little survival benefit in refractory VF or pulseless VT. Nevertheless, the current ACLS Guidelines state that they may be used in certain situations. The timing of antiarrhythmic use is not specified. We suggest that antiarrhythmic drugs be considered after a second unsuccessful defibrillation attempt in anticipation of a third shock.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      (300 mg IV with a repeat dose of 150 mg IV as indicated) may be administered in VF or pulseless VT unresponsive to defibrillation, CPR, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      (1 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV, then 0.5 to 0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 5 to 10 minutes) may be used if",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is unavailable.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"      (2 g IV, followed by a maintenance infusion) may be used to treat polymorphic ventricular tachycardia consistent with torsade de pointes. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Irregular wide complex'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Refractory VF or pulseless VT may be caused by an acute coronary syndrome (ACS), in which case percutaneous coronary intervention can be performed if the patient is successfully resuscitated and the procedure is feasible. Note that following cardiac arrest the ECG may be insensitive for ACS; cardiology consultation is needed for patients with return of spontaneous circulation (ROSC) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/4\">",
"     4",
"    </a>",
"    ]. Causes other than ACS can lead to SCA (",
"    <a class=\"graphic graphic_table graphicRef52416 \" href=\"UTD.htm?17/18/17708\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In summary, the ROSC in VF and pulseless VT hinges on early defibrillation and excellent CPR. Although, the 2010 ACLS Guidelines advocate the appropriate use of advanced airway management and treatment with specific medications, these interventions have not been shown to improve survival in SCA. Therefore, such interventions must never be initiated at the expense of performing excellent CPR and early defibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Asystole and pulseless electrical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asystole is defined as a complete absence of demonstrable electrical and mechanical cardiac activity. Pulseless electrical activity (PEA) is defined as any one of a heterogeneous group of organized electrocardiographic rhythms without sufficient mechanical contraction of the heart to produce a palpable pulse or measurable blood pressure. By definition, asystole and PEA are non-perfusing rhythms requiring the initiation of excellent CPR immediately when either is present (",
"    <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the 2010 ACLS Guidelines, asystole and PEA are addressed together because successful management for both depends on excellent CPR, vasopressors, and rapid reversal of underlying causes, such as hypoxia, hyperkalemia, poisoning, and hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"     18",
"    </a>",
"    ]. Asystole may be the result of a primary or secondary cardiac conduction abnormality, possibly from end-stage tissue hypoxia and metabolic acidosis, or, rarely, the result of excessive vagal stimulation. It is crucial to identify and treat potential secondary causes of asystole or PEA as rapidly as possible. Some causes (eg, tension pneumothorax, cardiac tamponade) result in ineffective CPR. Do not hesitate to perform invasive procedures to treat suspected secondary causes; if the patient is receiving CPR, there is little chance the intervention will make the situation worse. The accompanying tables describe important secondary causes of cardiac arrest (",
"    <a class=\"graphic graphic_table graphicRef52416 \" href=\"UTD.htm?17/18/17708\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After initiating CPR, treat reversible causes as appropriate and administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    (1 mg IV every three to five minutes). The 2010 ACLS Guidelines state that vasopressin may be given (40 units for the first 10 minutes of resuscitation) in place of the first or second epinephrine dose. As with VF and pulseless VT, evidence supporting the benefit of epinephrine in patients with asystole or PEA is limited and further study is needed. Neither asystole nor PEA responds to defibrillation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    is no longer recommended for the treatment of asystole or PEA. Cardiac pacing is ineffective for cardiac arrest and not recommended in the 2010 ACLS Guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, treatment for asystole and PEA consists of early identification and treatment of reversible causes and excellent CPR with vasopressor administration until either ROSC or a shockable rhythm occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3328761\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 ACLS Guidelines encourage the use of clinical and physiologic monitoring to optimize the performance of CPR and to detect the return of spontaneous circulation (ROSC) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/5\">",
"     5",
"    </a>",
"    ]. Assessment and immediate feedback about important clinical parameters, such as the rate and depth of chest compressions, adequacy of chest recoil between compressions, and rate and force of ventilations, can improve CPR. End-tidal carbon dioxide (EtCO2) measurements from continuous waveform capnography accurately reflect cardiac output and cerebral perfusion pressure, and therefore the quality of CPR. Sudden, sustained increases in EtCO2 during CPR indicate a ROSC while decreasing EtCO2 during CPR may indicate inadequate compressions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link&amp;anchor=H7#H7\">",
"     \"Carbon dioxide monitoring (capnography)\", section on 'Effectiveness of CPR'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link&amp;anchor=H8#H8\">",
"     \"Carbon dioxide monitoring (capnography)\", section on 'Return of spontaneous circulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from other physiologic monitors is less likely to be available in patients with SCA, but measurements obtained from arterial and central venous catheters provide useful feedback about the quality of CPR and ROSC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"     18",
"    </a>",
"    ]. Measurements of arterial relaxation provide a reasonable approximation of coronary perfusion pressure. During CPR, a reasonable goal is to maintain the arterial relaxation (or &ldquo;diastole&rdquo;) pressure above 20 mmHg. Central venous oxygen saturation (SCVO2) provides information about oxygen delivery and cardiac output. During CPR, a reasonable goal is to maintain SCVO2 above 30 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradycardia is defined conservatively as a heart rate below 60 beats per minute, but symptomatic bradycardia generally entails rates below 50 beats per minute. The 2010 ACLS Guidelines recommend that clinicians not intervene unless the patient exhibits evidence of inadequate tissue perfusion thought to result from the slow heart rate (",
"    <a class=\"graphic graphic_algorithm graphicRef63919 \" href=\"UTD.htm?1/16/1280\">",
"     algorithm 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"     18",
"    </a>",
"    ]. Signs and symptoms of inadequate perfusion include hypotension, altered mental status, signs of shock, ongoing ischemic chest pain, and evidence of acute pulmonary edema. Hypoxemia is a common cause of bradycardia; look for signs of labored breathing (eg, increased respiratory rate, retractions, paradoxical abdominal breathing) and low oxygen saturation. Mild symptoms may not warrant treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H12#H12\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If any significant symptoms are present in the setting of bradycardia, administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    (if easily done) and immediately prepare to treat the patient with transcutaneous pacing or an infusion of a chronotropic agent (dopamine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    ). Do not delay treatment with transcutaneous pacing or a chronotropic agent in order to give atropine. &nbsp;",
"   </p>",
"   <p>",
"    The initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    is 0.5 mg IV. This dose may be repeated every three to five minutes to a total dose of 3 mg. Do not give atropine if there is evidence of a high degree (second degree [Mobitz] type II or third degree) atrioventricular (AV) block [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/25\">",
"     25",
"    </a>",
"    ]. Atropine exerts its antibradycardiac effects at the AV node and is unlikely to be effective if a conduction block exists at or below the Bundle of His, or in transplanted hearts, which lack vagal innervation. Atropine may be harmful in the setting of cardiac ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=see_link\">",
"     \"Third degree (complete) atrioventricular block\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Before using transcutaneous pacing, assess whether the patient can perceive the pain associated with this procedure and if so provide appropriate sedation and analgesia whenever possible. Infusions of dopamine are dosed at 2 to 10",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    per minute, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    is given at 2 to 10 micrograms per minute. Each is titrated to the patient's response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If neither transcutaneous pacing nor infusion of a chronotropic agent resolves the patient&rsquo;s symptoms, prepare for transvenous pacing and obtain expert consultation if available. Patients requiring transcutaneous or transvenous pacing also require cardiology consultation, and admission for evaluation for permanent pacemaker placement.",
"   </p>",
"   <p>",
"    Common toxicologic causes of symptomatic bradycardia include supratherapeutic levels of beta-blockers, calcium channel blockers, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    . These poisonings are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/19/33081?source=see_link\">",
"     \"Beta blocker poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31736?source=see_link\">",
"     \"Calcium channel blocker poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=see_link\">",
"     \"Digitalis (cardiac glycoside) poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tachycardia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia is defined as a heart rate above 100 beats per minute, but symptomatic tachycardia generally involves rates over 150 beats per minute, unless underlying ventricular dysfunction exists [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"     18",
"    </a>",
"    ]. Management of tachyarrhythmias is governed by the presence of clinical symptoms and signs caused by the rapid heart rate (",
"    <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"     algorithm 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The fundamental approach is as follows: First determine if the patient is unstable (eg, manifests ongoing ischemic chest pain, acute mental status changes, hypotension, signs of shock, or evidence of acute pulmonary edema). Hypoxemia is a common cause of tachycardia; look for signs of labored breathing (eg, increased respiratory rate, retractions, paradoxical abdominal breathing) and low oxygen saturation.",
"   </p>",
"   <p>",
"    If instability is present and appears related to the tachycardia, treat immediately with synchronized cardioversion, unless the rhythm is sinus tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/26\">",
"     26",
"    </a>",
"    ]. Some cases of supraventricular tachycardia may respond to immediate treatment with a bolus of adenosine (6 to 12 mg IV) without the need of cardioversion. Whenever possible, assess whether the patient can perceive the pain associated with cardioversion, and if so provide appropriate sedation and analgesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H12#H12\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the stable patient, use the electrocardiogram (ECG) to determine the nature of the arrhythmia. In the urgent settings in which ACLS algorithms are most often employed, specific rhythm identification may not be possible. Nevertheless, by performing an orderly review of the ECG, one can determine appropriate management. Three questions provide the basis for assessing the electrocardiogram in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the patient in a sinus rhythm?",
"     </li>",
"     <li>",
"      Is the QRS complex wide or narrow?",
"     </li>",
"     <li>",
"      Is the rhythm regular or irregular?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More detailed approaches to rhythm determination in tachycardia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link\">",
"     \"Overview of the acute management of tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Regular narrow complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus tachycardia and supraventricular tachycardia are the major causes of a regular narrow complex arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"     18",
"    </a>",
"    ]. Sinus tachycardia is a common response to fever, anemia, shock, sepsis, pain, heart failure, or any other physiologic stress. No medication is needed to treat sinus tachycardia; care is focused on treating the underlying cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14742?source=see_link\">",
"     \"Sinus tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supraventricular tachycardia (SVT) is a regular tachycardia most often caused by a reentrant mechanism within the conduction system (",
"    <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"     algorithm 4",
"    </a>",
"    ). The QRS interval is usually narrow, but can be longer than 120 ms if a bundle branch block (ie, SVT with aberrancy or fixed bundle branch block) is present. Vagal maneuvers, which may block conduction through the AV node and result in interruption of the reentrant circuit, may be employed on appropriate patients while other therapies are prepared. Vagal maneuvers alone, (eg, Valsalva, carotid sinus massage) convert up to 25 percent of SVTs to sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. SVT refractory to vagal maneuvers is treated with adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link\">",
"     \"Overview of the acute management of tachyarrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of its extremely short half-life, adenosine (6 to 12 mg IV) is injected as rapidly as possible into a large proximal vein, followed immediately by a 20 mL saline flush and elevation of the extremity to ensure the drug enters the central circulation before it is metabolized. If the first dose of adenosine does not convert the rhythm, a second and third dose of 12 mg IV may be given. Larger doses (eg, 18 mg IV) may be needed in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    or theobromine, or who consume large amounts of caffeine; smaller doses (eg, 3 mg IV) should be given to patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , those with transplanted hearts, or when injecting via a central vein.",
"   </p>",
"   <p>",
"    Prior to injection, warn the patient about transient side effects from adenosine, including chest discomfort, dyspnea, and flushing, and give reassurance that these effects are very brief. Perform continuous ECG recording during administration. If adenosine fails to convert the SVT, consider other etiologies for this rhythm, including atrial flutter or a non-reentrant SVT, which may become apparent on the ECG when AV nodal conduction is slowed.",
"   </p>",
"   <p>",
"    If conversion attempts fail, initiate rate control with either an intravenous nondihydropyridine calcium channel blocker or a beta blocker. Agents to choose from include:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , and a number of beta blockers, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link&amp;anchor=H9#H9\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\", section on 'Pharmacologic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Irregular narrow complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irregular narrow-complex tachycardias may be caused by atrial fibrillation, atrial flutter with variable atrioventricular (AV) nodal conduction, multifocal atrial tachycardia (MAT), or sinus tachycardia with frequent premature atrial beats (",
"    <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"     algorithm 4",
"    </a>",
"    ). Of these, atrial fibrillation is most common [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial goal of treatment in stable patients is to control the heart rate using either a nondihydropyridine calcium channel blocker (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    15 to 20 mg IV over two minutes, repeat at 20 to 25 mg IV after 15 minutes, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    2.5 to 5 mg IV over two minutes followed by 5 to 10 mg IV every 15 to 30 minutes) or a beta blocker (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    5 mg IV for 3 doses every two to five minutes; then up to 200 mg PO every 12 hours). The management of atrial fibrillation and SVT is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link\">",
"     \"Multifocal atrial tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcium channel blockers and beta-blockers may cause or worsen hypotension. Patients should be closely monitored while the drug is given, and patients at greater risk of developing severe hypotension (eg, elders) often require loading doses that are below the usual range. Combination therapy with a beta blocker and calcium channel blocker increases the risk of severe heart block.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    is suggested in most instances for the management of acute atrial fibrillation with rapid ventricular response. Beta-blockers may also be used and may be preferred in the setting of an acute coronary syndrome. Beta-blockers are more effective for chronic rate control. For atrial fibrillation associated with hypotension,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    may be used (150 mg IV over 10 minutes, followed by 1",
"    <span class=\"nowrap\">",
"     mg/min",
"    </span>",
"    drip for six hours, and then 0.5",
"    <span class=\"nowrap\">",
"     mg/min),",
"    </span>",
"    but the possibility of conversion to sinus rhythm must be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/31\">",
"     31",
"    </a>",
"    ]. For atrial fibrillation associated with acute heart failure, amiodarone or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    may be used for rate control. Treatment of MAT includes correction of possible precipitants, such as hypokalemia and hypomagnesemia. The 2010 ACLS Guidelines recommend consultation with a cardiologist for these arrhythmias.",
"   </p>",
"   <p>",
"    Cardioversion of stable patients with irregular narrow complex tachycardias should",
"    <strong>",
"     NOT",
"    </strong>",
"    be undertaken without considering the risk of embolic stroke. If the duration of atrial fibrillation is known to be less than 48 hours, the risk of embolic stroke is low, and the clinician may consider electrical or chemical cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/32\">",
"     32",
"    </a>",
"    ]. A number of medications can be used for chemical cardioversion and the best drug varies according to clinical circumstance. The questions of whether chemical cardioversion is appropriate and which agent to select are reviewed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Regular wide complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;A regular, wide-complex tachycardia is generally ventricular in etiology (",
"    <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"     algorithm 4",
"    </a>",
"    ). Aberrantly conducted supraventricular tachycardias may also be seen. Because differentiation between ventricular tachycardia (VT) and SVT with aberrancy can be difficult, assume VT is present. Treat clinically stable undifferentiated wide-complex tachycardia with antiarrhythmics or elective synchronized cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cases of regular, wide-complex tachycardia with a monomorphic QRS complex, adenosine may be used for diagnosis and treatment. Do",
"    <strong>",
"     NOT",
"    </strong>",
"    give adenosine to patients who are unstable or manifest wide-complex tachycardia with an irregular rhythm or a polymorphic QRS complex. Adenosine is unlikely to affect ventricular tachycardia but is likely to slow or convert SVT with aberrancy. Dosing is identical to that used for SVT. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Regular narrow complex'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other antiarrhythmics that may be used to treat stable patients with regular, wide-complex tachycardia include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/min",
"    </span>",
"    IV),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (150 mg IV given over 10 minutes, repeated as needed to a total of 2.2 g IV over the first 24 hours), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    (100 mg IV over five minutes). A procainamide infusion continues until the arrhythmia is suppressed, the patient becomes hypotensive, the QRS widens 50 percent beyond baseline, or a maximum dose of 17",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is administered. Procainamide and sotalol should be avoided in patients with a prolonged QT interval. If the wide-complex tachycardia persists, in spite of pharmacologic therapy, elective cardioversion may be needed. The 2010 ACLS Guidelines recommend expert consultation for all patients with wide complex tachycardia.",
"   </p>",
"   <p>",
"    SVT with aberrancy, if",
"    <strong>",
"     DEFINITIVELY",
"    </strong>",
"    identified (eg, old ECG demonstrates bundle branch block), may be treated in the same manner as narrow-complex SVT, with vagal maneuvers, adenosine, or rate control. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Irregular narrow complex'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Irregular wide complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide complex, irregular tachycardia may be atrial fibrillation with preexcitation (eg, Wolf Parkinson White syndrome), atrial fibrillation with aberrancy (bundle branch block), or polymorphic ventricular tachycardia",
"    <span class=\"nowrap\">",
"     (VT)/torsades",
"    </span>",
"    de pointes (",
"    <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"     algorithm 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"     18",
"    </a>",
"    ]. Use of atrioventricular (AV) nodal blockers in wide complex, irregular tachycardia of unclear etiology may precipitate ventricular fibrillation (VF) and patient death, and is contraindicated. Such medications include beta blockers, calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and adenosine. To avoid inappropriate and possibly dangerous treatment, the 2010 ACLS Guidelines suggest assuming that any wide complex, irregular tachycardia is caused by preexcited atrial fibrillation.",
"   </p>",
"   <p>",
"    Patients with a wide complex, irregular tachycardia caused by preexcited atrial fibrillation usually manifest extremely fast heart rates (generally over 200 beats per minute) and require immediate electric cardioversion. In cases where electric cardioversion is ineffective or unfeasible, or atrial fibrillation recurs, antiarrhythmic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    may be given. The 2010 ACLS Guidelines recommend expert consultation for all patients with wide complex tachycardia. Dosing for antiarrhythmic medications is described above. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Regular wide complex'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treat polymorphic VT with emergent defibrillation. Interventions to prevent recurrent polymorphic VT include correcting underlying electrolyte abnormalities (eg, hypokalemia, hypomagnesemia) and, if a prolonged QT interval is observed or thought to exist, stopping all medications that increase the QT interval.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    (2 g IV, followed by a maintenance infusion) can be given to prevent polymorphic VT associated with familial or acquired prolonged QT syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A clinically stable patient with atrial fibrillation and a wide QRS interval",
"    <strong>",
"     KNOWN",
"    </strong>",
"    to stem from a preexisting bundle branch block (ie, old ECG demonstrates preexisting block) may be treated in the same manner as a narrow-complex atrial fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6563752\">",
"    <span class=\"h2\">",
"     Alternative methods for medication administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, ACLS medications should be given intravenously. When IV access cannot be established, intraosseous (IO) lines are safe, effective, and can be placed efficiently [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"     18",
"    </a>",
"    ]. Medication doses for IO administration are identical to those for IV therapy. If neither IV nor IO access can be established, some medications may be given via the tracheal tube. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=see_link\">",
"     \"Intraosseous infusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple studies have demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , vasopressin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    are absorbed via the trachea [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"     18",
"    </a>",
"    ]; however, the serum drug concentrations achieved using this route are unpredictable. If the patient already has peripheral, intraosseous, or central venous access, these are always the preferred routes for drug administration. When unable to obtain such access expeditiously, one may use the endotracheal tube while attempting to establish vascular or intraosseous access. At no point should excellent CPR be interrupted to obtain vascular access.",
"   </p>",
"   <p>",
"    Doses for tracheal administration are 2 to 2.5 times the standard IV",
"    <sup>",
"    </sup>",
"    doses and medications should be diluted in 5 to 10 mL of sterile water or normal saline before injection down the tracheal tube.",
"    <sup>",
"    </sup>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     POST-RESUSCITATION CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 ACLS Guidelines recommend a combination of goal-oriented interventions provided by an experienced multidisciplinary team for all cardiac arrest patients with return of spontaneous circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"     18",
"    </a>",
"    ]. Important objectives for such care include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optimizing cardiopulmonary function and perfusion of vital organs",
"     </li>",
"     <li>",
"      Managing acute coronary syndromes",
"     </li>",
"     <li>",
"      Implementing strategies to prevent and manage organ system dysfunction and injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management of the post-cardiac arrest patient is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35274?source=see_link\">",
"     \"Post-cardiac arrest management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TERMINATION OF RESUSCITATIVE EFFORTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining when to stop resuscitation efforts in cardiac arrest patients is difficult, and little data exist to guide decision-making. Factors associated with poor and good outcomes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=see_link\">",
"     \"Outcome of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physician survey data and clinical practice guidelines suggest that factors influencing the decision to stop resuscitative efforts include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration of resuscitative effort &gt;30 minutes without a sustained perfusing rhythm",
"     </li>",
"     <li>",
"      Initial electrocardiographic rhythm of asystole",
"     </li>",
"     <li>",
"      Prolonged interval between estimated time of arrest and initiation of resuscitation",
"     </li>",
"     <li>",
"      Patient age and severity of comorbid disease",
"     </li>",
"     <li>",
"      Absent brainstem reflexes",
"     </li>",
"     <li>",
"      Normothermia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More objective endpoints of resuscitation have been proposed. Of these, the best predictor of outcome may be the end tidal CO2 level following 20 minutes of resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. End tidal CO2 values are a function of CO2 production and venous return to the right heart and pulmonary circulation. A very low end tidal CO2 (&lt;10 mmHg) following prolonged resuscitation (&gt;20 minutes) is a sign of absent circulation and a strong predictor of acute mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. It is crucial to note that low end tidal CO2 levels may also be caused by a misplaced (esophageal) endotracheal tube, and this possibility needs to be excluded before the decision is made to terminate resuscitative efforts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resuscitation in the emergency department does not appear to be superior to field resuscitation by emergency medical services (EMS) personnel. Therefore, EMS personnel should not be required to transport all victims of sudden cardiac arrest to the hospital, if further resuscitation is deemed futile [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large, retrospective cohort studies have assessed criteria (BLS and ALS) for the prehospital termination of resuscitative efforts in cardiac arrest, initially described in the OPALS study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Both BLS and ALS criteria demonstrated high specificity for identifying out-of-hospital cardiac arrest patients with little or no chance of survival. Studies of another clinical decision rule suggest that it too accurately predicts survival and would reduce unnecessary transports substantially if implemented [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/42,46\">",
"     42,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to a systematic review of 12 small trials, most of which studied convenience samples of patients with sudden cardiac arrest (n=568), bedside echocardiography may be helpful for assessing prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/33/13850/abstract/47\">",
"     47",
"    </a>",
"    ]. In this review, the pooled sensitivity and specificity of echocardiography to predict the return of spontaneous circulation (ROSC) were 91.6 and 80 percent respectively (95% CI for sensitivity 84.6 to 96.1%; 95% CI for specificity 76.1 to 83.6%). Of the 190 patients found to have cardiac wall motion, 98 (51.6 percent) achieved ROSC, whereas only 9 (2.4 percent) of the 378 without cardiac wall motion did so. Limitations of the individual studies prevented the authors from assessing survival to discharge or survival with good neurologic function.",
"   </p>",
"   <p>",
"    The authors of this review emphasize that echocardiography results should not be the sole basis for terminating resuscitative efforts but may serve as an adjunct to clinical assessment. Bedside echocardiography must never interfere with resuscitation efforts, and should not interrupt or delay resumption of CPR, except in cases where the ultrasound is being obtained strictly to confirm absence of wall motion when a decision to terminate resuscitative efforts is imminent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/12/25795?source=see_link\">",
"       \"Patient information: Ventricular fibrillation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10125862\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiopulmonary resuscitation (CPR) and early defibrillation for treatable arrhythmias remain the cornerstones of basic and advanced cardiac life support (ACLS). Excellent chest compressions without interruption are the key to successful CPR (",
"      <a class=\"graphic graphic_table graphicRef83671 \" href=\"UTD.htm?37/32/38411\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Excellent basic life support and its importance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The performance of teams providing ACLS improves when there is a single designated leader and the team practices clear, closed-loop communication. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Resuscitation team management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Begin properly performed cardiopulmonary resuscitation (CPR) immediately for any patient with suspected cardiac arrest. Other initial interventions for ACLS include administering oxygen, establishing intravenous access, placing the patient on a cardiac and oxygen saturation monitor, and obtaining an electrocardiogram (ECG). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Initial management and ECG interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In adults, properly performed chest compressions take priority over ventilation during the initial period of basic life support. When ventilating the patient in cardiac arrest, give 100 percent oxygen, use low respiratory rates (approximately 8 breaths per minute), and avoid hyperventilation, which is harmful. (See",
"      <a class=\"local\" href=\"#H4318336\">",
"       'Airway management during ACLS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the purposes of ACLS, ECG interpretation is guided by three questions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Is the rhythm fast or slow?",
"     </li>",
"     <li>",
"      Are the QRS complexes wide or narrow?",
"     </li>",
"     <li>",
"      Is the rhythm regular or irregular?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The basic approach and important aspects of management for each arrhythmia covered by the 2010 ACLS Guidelines are discussed in the text and summarized in the accompanying algorithms (",
"      <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"       algorithm 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef61966 \" href=\"UTD.htm?12/19/12598\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef63919 \" href=\"UTD.htm?1/16/1280\">",
"       algorithm 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"       algorithm 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management of specific arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/1\">",
"      DeBard ML. The history of cardiopulmonary resuscitation. Ann Emerg Med 1980; 9:273.",
"     </a>",
"    </li>",
"    <li>",
"     Highlights of the History of Cardiopulmonary Resuscitation (CPR). American Heart Association 2006. www.americanheart.org (Accessed on March 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/3\">",
"      Hermreck AS. The history of cardiopulmonary resuscitation. Am J Surg 1988; 156:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/4\">",
"      Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/5\">",
"      Hazinski MF, Nolan JP, Billi JE, et al. Part 1: Executive summary: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation 2010; 122:S250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/6\">",
"      Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/7\">",
"      Valenzuela TD, Kern KB, Clark LL, et al. Interruptions of chest compressions during emergency medical systems resuscitation. Circulation 2005; 112:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/8\">",
"      Eilevstj&oslash;nn J, Kramer-Johansen J, Eftest&oslash;l T, et al. Reducing no flow times during automated external defibrillation. Resuscitation 2005; 67:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/9\">",
"      Wik L, Kramer-Johansen J, Myklebust H, et al. Quality of cardiopulmonary resuscitation during out-of-hospital cardiac arrest. JAMA 2005; 293:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/10\">",
"      Yu T, Weil MH, Tang W, et al. Adverse outcomes of interrupted precordial compression during automated defibrillation. Circulation 2002; 106:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/11\">",
"      Abella BS, Sandbo N, Vassilatos P, et al. Chest compression rates during cardiopulmonary resuscitation are suboptimal: a prospective study during in-hospital cardiac arrest. Circulation 2005; 111:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/12\">",
"      International Liaison Committee on Resuscitation. 2005 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Part 2: Adult basic life support. Resuscitation 2005; 67:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/13\">",
"      Blum RH, Raemer DB, Carroll JS, et al. Crisis resource management training for an anaesthesia faculty: a new approach to continuing education. Med Educ 2004; 38:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/14\">",
"      Reznek M, Smith-Coggins R, Howard S, et al. Emergency medicine crisis resource management (EMCRM): pilot study of a simulation-based crisis management course for emergency medicine. Acad Emerg Med 2003; 10:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/15\">",
"      Murray WB, Foster PA. Crisis resource management among strangers: principles of organizing a multidisciplinary group for crisis resource management. J Clin Anesth 2000; 12:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/16\">",
"      Hunziker S, Johansson AC, Tschan F, et al. Teamwork and leadership in cardiopulmonary resuscitation. J Am Coll Cardiol 2011; 57:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/17\">",
"      DeVita MA, Schaefer J, Lutz J, et al. Improving medical emergency team (MET) performance using a novel curriculum and a computerized human patient simulator. Qual Saf Health Care 2005; 14:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/18\">",
"      Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/19\">",
"      Berg RA, Hemphill R, Abella BS, et al. Part 5: adult basic life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/20\">",
"      Hasegawa K, Hiraide A, Chang Y, Brown DF. Association of prehospital advanced airway management with neurologic outcome and survival in patients with out-of-hospital cardiac arrest. JAMA 2013; 309:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/21\">",
"      Martens PR, Russell JK, Wolcke B, et al. Optimal Response to Cardiac Arrest study: defibrillation waveform effects. Resuscitation 2001; 49:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/22\">",
"      Schneider T, Martens PR, Paschen H, et al. Multicenter, randomized, controlled trial of 150-J biphasic shocks compared with 200- to 360-J monophasic shocks in the resuscitation of out-of-hospital cardiac arrest victims. Optimized Response to Cardiac Arrest (ORCA) Investigators. Circulation 2000; 102:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/23\">",
"      Schwarz B, Bowdle TA, Jett GK, et al. Biphasic shocks compared with monophasic damped sine wave shocks for direct ventricular defibrillation during open heart surgery. Anesthesiology 2003; 98:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/24\">",
"      Hagihara A, Hasegawa M, Abe T, et al. Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest. JAMA 2012; 307:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/25\">",
"      Brady WJ, Swart G, DeBehnke DJ, et al. The efficacy of atropine in the treatment of hemodynamically unstable bradycardia and atrioventricular block: prehospital and emergency department considerations. Resuscitation 1999; 41:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/26\">",
"      Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967; 29:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/27\">",
"      Lim SH, Anantharaman V, Teo WS, et al. Comparison of treatment of supraventricular tachycardia by Valsalva maneuver and carotid sinus massage. Ann Emerg Med 1998; 31:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/28\">",
"      Wen ZC, Chen SA, Tai CT, et al. Electrophysiological mechanisms and determinants of vagal maneuvers for termination of paroxysmal supraventricular tachycardia. Circulation 1998; 98:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/29\">",
"      Delaney B, Loy J, Kelly AM. The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis. Eur J Emerg Med 2011; 18:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/30\">",
"      Gebril A, Hawes S. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: is intravenous adenosine effective and safe in patients presenting with unstable paroxysmal supraventricular tachycardia? Emerg Med J 2012; 29:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/31\">",
"      Cybulski J, Ku��akowski P, Makowska E, et al. Intravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias. Clin Cardiol 1996; 19:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/32\">",
"      Michael JA, Stiell IG, Agarwal S, Mandavia DP. Cardioversion of paroxysmal atrial fibrillation in the emergency department. Ann Emerg Med 1999; 33:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/33\">",
"      Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/34\">",
"      Mohr M, Bahr J, Schmid J, et al. The decision to terminate resuscitative efforts: results of a questionnaire. Resuscitation 1997; 34:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/35\">",
"      Marco CA, Bessman ES, Schoenfeld CN, Kelen GD. Ethical issues of cardiopulmonary resuscitation: current practice among emergency physicians. Acad Emerg Med 1997; 4:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/36\">",
"      de Vos R, Oosterom L, Koster RW, de Haan RJ. Decisions to terminate resuscitation. Resuscitation Committee. Resuscitation 1998; 39:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/37\">",
"      Bailey ED, Wydro GC, Cone DC. Termination of resuscitation in the prehospital setting for adult patients suffering nontraumatic cardiac arrest. National Association of EMS Physicians Standards and Clinical Practice Committee. Prehosp Emerg Care 2000; 4:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/38\">",
"      Horsted TI, Rasmussen LS, Lippert FK, Nielsen SL. Outcome of out-of-hospital cardiac arrest--why do physicians withhold resuscitation attempts? Resuscitation 2004; 63:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/39\">",
"      Levine RL, Wayne MA, Miller CC. End-tidal carbon dioxide and outcome of out-of-hospital cardiac arrest. N Engl J Med 1997; 337:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/40\">",
"      Grmec S, Klemen P. Does the end-tidal carbon dioxide (EtCO2) concentration have prognostic value during out-of-hospital cardiac arrest? Eur J Emerg Med 2001; 8:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/41\">",
"      Ahrens T, Schallom L, Bettorf K, et al. End-tidal carbon dioxide measurements as a prognostic indicator of outcome in cardiac arrest. Am J Crit Care 2001; 10:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/42\">",
"      Morrison LJ, Visentin LM, Kiss A, et al. Validation of a rule for termination of resuscitation in out-of-hospital cardiac arrest. N Engl J Med 2006; 355:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/43\">",
"      Ong ME, Jaffey J, Stiell I, et al. Comparison of termination-of-resuscitation guidelines for basic life support: defibrillator providers in out-of-hospital cardiac arrest. Ann Emerg Med 2006; 47:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/44\">",
"      Stiell IG, Nesbitt LP, Pickett W, et al. The OPALS Major Trauma Study: impact of advanced life-support on survival and morbidity. CMAJ 2008; 178:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/45\">",
"      Ruygrok ML, Byyny RL, Haukoos JS, Colorado Cardiac Arrest &amp; Resuscitation Collaborative Study Group and the Denver Metro EMS Medical Directors. Validation of 3 termination of resuscitation criteria for good neurologic survival after out-of-hospital cardiac arrest. Ann Emerg Med 2009; 54:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/46\">",
"      Morrison LJ, Verbeek PR, Zhan C, et al. Validation of a universal prehospital termination of resuscitation clinical prediction rule for advanced and basic life support providers. Resuscitation 2009; 80:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/33/13850/abstract/47\">",
"      Blyth L, Atkinson P, Gadd K, Lang E. Bedside focused echocardiography as predictor of survival in cardiac arrest patients: a systematic review. Acad Emerg Med 2012; 19:1119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 278 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-1B6D22AFDF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13850=[""].join("\n");
var outline_f13_33_13850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10125862\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVIDENCE BASED GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRINCIPLES OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Excellent basic life support and its importance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Resuscitation team management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Initial management and ECG interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4318336\">",
"      AIRWAY MANAGEMENT DURING ACLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT OF SPECIFIC ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3328729\">",
"      Sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Ventricular fibrillation and pulseless ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Asystole and pulseless electrical activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3328761\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bradycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Regular narrow complex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Irregular narrow complex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Regular wide complex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Irregular wide complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6563752\">",
"      Alternative methods for medication administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      POST-RESUSCITATION CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TERMINATION OF RESUSCITATIVE EFFORTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10125862\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/278\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/278|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?28/15/28912\" title=\"algorithm 1\">",
"      Adult BLS algorithm for healthcare providers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/63/44022\" title=\"algorithm 2\">",
"      Adult cardiac arrest algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/16/1280\" title=\"algorithm 3\">",
"      Adult bradycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/21/20819\" title=\"algorithm 4\">",
"      Adult tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/278|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/19/12598\" title=\"figure 1\">",
"      ACLS cardiac arrest circular figure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/278|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/32/38411\" title=\"table 1\">",
"      Key principles in the performance of ACLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/37/5723\" title=\"table 2\">",
"      Manual defibrillation performance bundle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/18/17708\" title=\"table 3\">",
"      Treatable conditions associated with cardiac arrest",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=related_link\">",
"      Basic life support (BLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/19/33081?source=related_link\">",
"      Beta blocker poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31736?source=related_link\">",
"      Calcium channel blocker poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/55/25466?source=related_link\">",
"      Devices for difficult emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28906?source=related_link\">",
"      Direct laryngoscopy and tracheal intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=related_link\">",
"      Intraosseous infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=related_link\">",
"      Multifocal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=related_link\">",
"      Outcome of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/12/25795?source=related_link\">",
"      Patient information: Ventricular fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35274?source=related_link\">",
"      Post-cardiac arrest management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14742?source=related_link\">",
"      Sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=related_link\">",
"      Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35448?source=related_link\">",
"      Therapies of uncertain benefit in basic and advanced cardiac life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=related_link\">",
"      Third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_33_13851="Sterilization failure rates";
var content_f13_33_13851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sterilization failure by method",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Method",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pregnancies per 1000 procedures after 5 years / 10 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postpartum partial salpingectomy",
"      </td>",
"      <td>",
"       6.3 / 7.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Laparoscopic unipolar coagulation",
"      </td>",
"      <td>",
"       2.3 / 3.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Falope ring",
"      </td>",
"      <td>",
"       10.0 / 17.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Interval partial salpingectomy",
"      </td>",
"      <td>",
"       15.1 / 20.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bipolar coagulation",
"      </td>",
"      <td>",
"       16.5 / 24.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Spring clips",
"      </td>",
"      <td>",
"       31.7 / 36.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       All methods",
"      </td>",
"      <td>",
"       13.1 / 18.5",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Peterson, HB, Xia, Z, Hughes, JM, et al. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996; 174:1161.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13851=[""].join("\n");
var outline_f13_33_13851=null;
var title_f13_33_13852="Lab findings immunodeficiency";
var content_f13_33_13852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F70391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F70391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory findings in humoral immunodeficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Flow",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Serum lg",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Specific antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Protein",
"       </td>",
"       <td class=\"subtitle2\">",
"        Poly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        XLA",
"       </td>",
"       <td>",
"        Very low/absent B cells",
"       </td>",
"       <td>",
"        Very low/absent",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td colspan=\"1\">",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AID/UNG",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Very low IgG, NL or high IgM",
"       </td>",
"       <td>",
"        IgM only",
"       </td>",
"       <td>",
"        IgM only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CVID",
"       </td>",
"       <td>",
"        Variable low T and/or low B",
"       </td>",
"       <td>",
"        Variable, occ. very low/absent",
"       </td>",
"       <td>",
"        Usually low",
"       </td>",
"       <td>",
"        Usually low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IGAD",
"       </td>",
"       <td>",
"        NL, occ. abnormal",
"       </td>",
"       <td>",
"        Absent IgA",
"       </td>",
"       <td>",
"        Variable, usually NL",
"       </td>",
"       <td>",
"        Variable, usually NL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IGGSD",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        1 or more low IgG subclass",
"       </td>",
"       <td>",
"        Usually NL",
"       </td>",
"       <td>",
"        Often low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SAD",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Usually NL",
"       </td>",
"       <td colspan=\"1\">",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        THI",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Low IgG",
"       </td>",
"       <td>",
"        Usually NL",
"       </td>",
"       <td>",
"        Usually NL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AID: activation-induced adenosine deaminase deficiency; CVID: common variable immunodeficiency; Flow: flow cytometry; IG: immunoglobulin; IGAD: IgA deficiency; IGGSD: IgG subclass deficiency; NL: normal; Poly.: polysaccharide; SAD: specific antibody deficiency (with normal immunoglobulins); THI: transient hypogammaglobulinemia of infancy; UNG: uracil nucleoside glycosylase deficiency; XLA: X-linked agammaglobulinemia.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13852=[""].join("\n");
var outline_f13_33_13852=null;
var title_f13_33_13853="Cryos and LFTs after interferon";
var content_f13_33_13853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serologic response to interferon alfa in mixed cryoglobulinemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 271px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Efficacy of interferon alfa in 43 patients with hepatitis C virus-induced chronic liver disease and cryoglobulinemia as determined by the disappearance of circulating cryoglobulins and normalization (responders, n = 28) or lack of normalization (nonresponders, n = 15) of plasma aminotransferase levels. Cryoglobulins were more likely to disappear in aminotransferase responders - 57 versus 33 percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lunel F, Musset L, Cacoub P, et al. Gastroenterology 1994; 106:1291.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13853=[""].join("\n");
var outline_f13_33_13853=null;
var title_f13_33_13854="Reversible benefit ERT on BMD";
var content_f13_33_13854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Reversible benefit of estrogen replacement therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 260px; background-image: url(data:image/gif;base64,R0lGODlhFgIEAeYAAP///4CAgH9/fwAAAAAz//8AAICZ/z8/P8DAwL+/v0BAQP9wcMDN/zAwMCAgIA8PD09PT29vb9DQ0B8fH8/Pz6CgoK+vr5+fn3BwcPDw8C8vLyBN/19fX+Dg4P8QEBAQEP/w8I+Pj5CQkN/f3+/v70Bm/3CN//9AQLCwsP+goP/AwH+Z//+AgFBQUP9QUP8gIBBA//9gYP/g4NDZ/2CA///Q0LDA//+wsP8wMFBz/+Dm/5Cm/2BgYP+QkDBZ//Dz/6Cz//9/f7/M//9PT//f3/8PDz9m//+/v//Pz1BZfxAmgI8Wb385n99QUAAZf39pzwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAWAgQBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChw4cQI0qcSNESggAYM2rcyLGjx48gQ4ocSbKkSY8IKqrMFuCAgJcwY8qcSbOmzZs4c+rcybPnzAMBhCGQMChDhQAVMhDqMHSlU0EBBDgUEPSXhAADFAxqkHVAg6JctT5dGXVqVV8KBmQVhGJACwAt/wagEIRBrdixFcs2pBoMwVoAWIMGBuAXq9iLG1PiXaiXIV9gfsUODpzBAYbIghBnVHB2McLGCx//wgxAxAAMAOqK8KvW7iGMnhWCNiRkhe3btoUYSsCb96YIBwBcOEDhEIUDFzgdiFBo+STniUT3kmC6AYIMHQY4QOBgQIcMCBBUJ2oIduzPUhOtIMC+PfsVhlqrPZRgQPpHBwYASCBgBH37nAwQHCECJCeJgIpIx0taraVUQXcOVEAIaeV1dh5BsxWynnvtwVeIWr0JEsIBy43AgYBSFUiBVMMdAIEFgljg4gT68ecfCcBxUFx99wkyAnAvAmABBAeE4KMAFnBAnP+MzAGAokuCFLgfkkrCuB+REZAQ5QEnDoiIgtaYd2FBGRKyIYcEeEiIWi8ld2IEAmiQgAYDTBDcAA/MBwGcNI5gwQAaCEAjAAIMkAAAGjwQ5wMj8EgICQ8oWuUAew7AXH0C4jkBjcnhGQEEAxiJYKEP5DeAn5RGQCkAqkJQqJeHgFmNmGO2w4ABuOZqAAONzFbbbUagyZ4RK+g2iHzBgerqoY46qcEgIwhwAI0JgOpffoQaSoGlQobarIgDGDgCqFomuh+A2DqKIAkIjmooq4aC+tKgD0wgCILRWRimvrWmY4CwBvTaIwC/2hassMQae69+g5DAAZ0DWNAsviM8oMH/BScmgC0A2BbKG4A8fpvtoYJsnC66NQKIb7vBeTxyfjE5OSC+X/JLDa39qvMvmgEzUuYgZ3Ko5rH2vQQAByEkoGrSlMKIb30QaGxooUgO6nK91Q5AgcjbynkBBCHY9ycE50p1slSAJnCiqC2/63HYUSfJccQX0ByrzdPgnHM5DABhwAYAC6xI0O4NvXBrhOb5QJP5PSDzICdabCgJ+W2qn8sU0DlBciILCbFUEeQJgZaOnu1kntw+7vLqNK5KAY35wWqIrDfjvbczt+qKK6+C6HBrDj4QsEEOBuQQuM8DayhsmvrQnrfttzOzM4clmFACATBUDwTvgkzvXs+L/CxI/8G4Fds89NDoHf0z3rdXwq46JNI+e+ArIn5Bzkuj/vq35K4794XwnQFoELzjKWJ+BKhfIu5HkPxFY3/8qwUCwdc368GAANXbAQNMYMBE+E9XAFxg8joxnOIQooSmgM4ggBMLB6YPfRGEBQJLkAPA+YB4DIgfISYoCgZiwkaPG1koJia7C4ywc6Jw4TMgGENZzHB7i+BhKHzYCCNqSUor4k1/6jaB/hQqBFUqRIFGxAEt4YhLJlSRVEggrSB1CW1F4pKWjBgjInFAbSgCABtdBKNoJcACyaGAkrI0pSQdwEomQuPsYOgMJgbkg7kKYf90tztE9M0AJbhgB+W3yU5Qkf8RYbPACPAErxUZSlWlMmWp1OIfommARhxAlKIS5R88zSdRcdKa5u4EKFjOTTiUEoCrdinLXG7NlgeoWKAslq1VnkqZAojUIrfhSIBIURdSFCDwhEc8G8zgmoqAZCWnOEJJjDICIaDTnOzlMny5TFUku1dw2EUcbv1JVM8CwLZcciIBEFGPCMJW2ALFOQDtUwD9rE+TQlnKdxoqbByQ1rsIxMhmVPMf4MQFAn1wveyZAIqFyOgsPsmICWhgORp4kxDd6baJylOejlLXgOrjkpd8LD0rC87GJGqpmKLIps1a3dRayp8BRPQlrRyEEhtZ0X3owHg84wUH0VSCHEaxk7L/IOkiVKW1QkVspRNIQLSIuqaZBQdroCoOzSJ1gQSEoK1NC2JA9ROCCCSgblGLK1vdCtf0bCtqE3CcUBPQNYlFwIRKbeoyLqqPGezABzAAHJpgYIIZ0EKABFxeAhshzl3hQquK2JbjRBullnaVrMcyqz41ZyCaUQBUdYJR4+SqU/1YoHWjm9toYTsBiQFIEBegkQaKM1jPqUUDSY2SYpXBWHvMwAQbgAENbAAABNLABJHdgQ470VkAVjCTGDSBBn8gUmSAth9Ltehy32ED6G7ABNQdhBRtQAMMAuEHheiuIxBIvBoS4IbwM0R5j3FefqSXGc1lLw0iW9lDgPMHQLje/3Tli1UHC2sDBgDpAStsjALv48CLXS84Ols8GPhgB5b1ICU9awgd7CC6lS3vDBiwg+Jdb3kKDOeKJWnechoExMwV8TcQuAHtguK5mkSTCS5JgxIAbgMloEGGGUBeDnfDw+cTCnkAYBSkKIXLRwlABxCR4HEMuBP1FRYNDaDBFAtYWE+QQTmwjAm7NYdh0gCyK67yFwCExStQac0HxlyheDhWshzK8SfOHFJhMcEDL1hADcRBZ0IAR5HCwdIcSWQkLvYnkcshQQJo5M8rhZoZem4Fg8TSlrfEZS4IGHNc+FXmbjw3ujSAaqJLwegdBu4GC3iBB2Jwg29UehBdDB07g/8ZVlV9KlSoJI7GEGrUC+QJOWNrFaqFzArSTGYAneHBACSkGYxwZh3t3cB749trTbRbEPodRA1YgIMCuCAFIKCmjyOhtAPkCQD1EgQJINXFVwVROEqaqyDkJSg8JyPVrfA2uAEzcUFIANCE2ci5u6Ff+jLYzd2z8ibizQkZ9MAFBThBD+QsiAUU4OULSN++HzE2C9Dp4E4quJTw5Wya/nJuMVsGxLv9F9OgRjWCqMAHGvDlQneDyCZGMSLeLQwQpMAFHsDBAmLw8q7HvJEzdwTVbqsfUCUtavK6K9rCOoL8AHKuFqAA3P4YS6FzWxXU8cp1srOd7ozZNB/AAFJec/f/Y/B3u5bc8TRuwPWud32JYW8ECTQ3KIflaQIjsDyeUqQWClDg2giyQJ6M1PBV2R0YDFKLgyAkIQCkvs+EqLX0RP4Nx3c93xaNfECGXgzZI8OxBYxqOmzfdResfLG6BwjvieF7YtxaujagOjdc7vgFWB3lOGDBpAmc/H8sfxjNpwXJ071uCgs/HdQvwNcHwXhIL0AFve++P74vjPDPYoIefy/IQ37+etQg2MN2A7j3C8dmD/QXDPbnRMtzYvtHCCSHDzXQA/V2b+m3frdQgPVwgMCQgLEgfQQhAyngAbZngbWAgfSggQRYeLDwVLSXEMRXALlggvOAgr7AgawAfJHV/4II8YLFdoHyh14qWH9BeAkPSAjPN2EeWBAv+AIv0AMDmFU/aGBDuIFTWAkZRX7w5Wv9FxHpB3MAcAMn4AELwHKxIIPyQIO9YIOXMF8Lpn+HUIRc6HWEUANc5wLwBwtmGA9oyAtqaAkzlANR14BNJAggwAJZlwKvkIfwsIe70IdWeGFGNoiMkAI44AEsMIAVSAoMhARD0HVDQASI0BvxpEKRgELTwIi64IiUkISDqAIoFwP/N4KjcD9IUAS2VwSgGB+t8QBqJTuP4DKnWIU1KIyRcGg6KImEIAMLIILEN4v71onENwSHMB9w8zjVwmkCNyJFokdtBCNfBAEQYEJDsv+NyoCKMViFcHiEuvY9yDgJIPCCzlgIRxAE9BgEL/hy9HgEa5Iyd9IyEZUfyZEfERA6xUQnpuQS0pRtqYMM5vhZVXhNWBhfcNiOjQCPPTQw81iP91gA+biPudQp8xQCEEAnArAtdTcCB9VPDpU15eI4D0eMfPiQAJN/DUaRn9CFL2eH5KQIGzmNAoIcL5UoIRA2/vRb51JT/jRYJuNwxtCQFyiTwsKANjkKFViIh/gJ9wONtieNuvghd9JsABIpFmBzAPcAbfVWXyR6jkOUY1OOMNmIULlrU8kKlGiJT4gJ90MEtuh4uOiTXglMmSIVr6UWwTGYsUUqdWJCoUMpWvL/ktQ0hSy4hXOZCq5YALCoCQxEBFr5iVL4mJmAg4jGjpPpCsroASfQg5agiO/glLYQfkdIXaw4mp4AAj3AhE5YCarpDqzJCU0hCF2WFIOAAgEgAoTmdJEQkQ6oeLIZC2AohpnoCLnZDruZCXx2F3/2FanhFR8waISHCM8JADQpiMvJCzXwArIoOHvxlp+wamzhFnAhFxkwAB9QGqeRcRqxcYWAk02QBErgBEqQBCcRoAI6oARaoAZ6oAiaoAo6EhaJPGbRF3/xbQGAGRSqcfzygguaoRq6oRzaoR76oR7RoOEThR+mnp8gcYIBbhQKe4OgPiI6nsfwoiL0oJBRdPWp/xoX9xWt1p2GIKMwSgw4SYIzmp7AkHfWgR3awR3eAQDdgQJx0XqFoD446QGI+KPI8J0+g5Q+saVc2qVe+qVfChSoJx+rpx2tJwFcEXhkZjMVCIYvUKVWig3lBqJ0WqcZqhgsUVEqEIaXGKd+SiaKtad2+aeECg0SQGiHmgqyJ6h9WqiOmgwbFwB3YQrNx6h3+aiYOh0K8AEOoACbOqmlYH8qEAODmqmmugusIWhzgQocKAOkGgNyhqWnOquugAFQqgpq6KoFUG/VR6u+2goZIAIZcauhWoUy4KO/mqyi8HqgqonCiKzKGq2doHfhsWWU+qzER4bSuq2d0AAmaj/CiP+TYRgDd8it5ooJGOAAw6qoxJiJVnkC5Xqu8hoJzMqup/Cu8Tqv+qoIEhAe1WqvqICv+zqwiSCcHRAA1lqsqyCwBNuw2TkACNACPACwdPkCpwkAsuqwyvoBPGAdkkqxrZACwnaeGhutEKsACMADzTqL3+oI0FqypqoADeAAcSECIOsKL6itMEurEvABasF0N9sKL+h+27eztNqbQcsKQfqFwfYCxGa0mdoCX9EBH9CysWe1jSCr/1eJ93apUAujckEXK+sIXbaqYDacTRelWJsJJncC9nZ8g5CxXzuIYZsaY8sIGcAVXIEaedsVH5C2Lbq2m3B9u9oDsdirc9uOLRD/eEg3CUbHpN7hF1+RFikxp/hJDO33sgsxkYm7CBLQHV4BuI+AFahBuX07sxNrn5shuKGguQoRm3MrAf2asJGQHVnhs9fBA5waujyKDC/YtRLxbpybnJTEY5jqqdSJFN1Bn0Exa717DDgZAyeXcnDbEPzFANiLvfj1ZpLJvXJJqyiAnZdQARFbnxWgd1xBrFDBuqHwndeXdZLGEERWAvRLvxwCZU4mLDSQvQwgiLArm/VKCWqhroOAAT5LwM+7eDHAhAuAmnKrD4w2YwyQZvdbv/nrHvQbmu2haJiKAZ7qqajBquz7Cv8nbDGAcojbDz+wjhvcCGf2A9hLwaLZuZOg/4q/YHKuGw/klYPd670zzEk9/KhoCrEOYLMiXHvEJ735Sg9AAGXYq5xXFcTm972z2gDbiQAenLTY8IIs4ALmeQILkAJF+w4M4AMbEF9+SHv/O5pygbIfe8TesLSEqAJd/MVhvH0PzA06kEk7oAnDOwh/XKgfIAIKgAIOkLqnYMPBkMcgQMdhuKsk6w0/UF8GsL00zAlY0SBavA7HSnw3oLPYsMM0gHiXzAmE3AJmm8gj7LvE57amyQIq4LXH0F1NXFWlDApIi6urHKPNCAA1kAIL4LYv4AKwfKl5LEHLswHGe8uX0Lcsqsr0IMeF8MvBXADDDMsYG8m5YF3MDArn2/8A6bsKilwNxzwIKtADMcCrvbwLa9zNC4Sd3irOu+wNOSxDx+jOo6uuAdCpgwfHClHPryDDLYzPmCwfruHPCSHNuMAAGjzQBK0Jc9rP0MwQ6VeJYyx+TuY39/zQMSkRIQinsqADC1bJABDIHE2FE6ECligLVUYDlnzSz0MRNYADLiDLp7AD2UPKMK0/82wOIHACOADKpmADG+ADy7zTS9TT57CMF00KDJDRSJ2nTpECBQDSoiDSMEDSUY0N4wyBYugJFfgDHGQCL73VwlC2hNBlNtPV+CADOHACNi0JOLkEOaDTZg0Mp1ufANCzWeEAa4oXIOACONDUlADQd40Lj+v/d5BrrZar1OxgiEsMCSDYeLZ32B1Wn5R7cQ7QHW+huubm2Ozw0ZEAAsBmnsb3gidg1ZbtC7a7qRAruQgQzsa5GDUwbNnshYYAbPV2AtjccrYXAyL7Aiwg1KudC1fxIPpxcVoxGLO9GCBQiefpyLvawN4ph4IwqvaGmsWtC+QbFyHcpFyBp1c7Ju9IfCgXaQJYCbRpm3G93a8wwGcxxB+gvutbKy+YAsRNCTfwipHt3uAH2u9g2JLNAkyIb3Fr3f7d0WOi0J+QAuN6uAie4OfYL+W8CaUp4BKuy9yK4RmO0Mr6gu/X4U/JrdELgMTW3iI+0dv6nRE4gfid4q7A1jAK/4LYZ7gwruE7S9qkGmn9feOeIOOEqgIA6La47eOeBOBTicJdR66xbOSYieQ2idpEnnInQMwskAIq0OS3rX5OnsBfK6KNrAIpwAJdfAJT/ttdrraXDND3qHVi3OVA7qgMzpPE18hdLIK8/cn5GeF3HedyzueL8KIycAMs4MrEjN0p3OdQfqpzPofArM6Ot9p+vq8VPggcXsqTzsyXfsmZfsuNjtSd7umAvtWhnua0itaE0K/FqeamftJ5HcJ77bNrveitDqOJvaR+phZV0di1ztGk63oQCxiBV3G83usE3dq4e3HCWXHNbezMfNzLm8mtQWu07uyj2d31yRQpOwA8sP/qgWvt+AzfUcrsrA7u7l3q5n6u6J7u3Lru7C6t7v7uyhrv8v6r9F7vtHrv+H6q+r7vmdrv/v6oAB/whbo/EW2nCJ/wCh8S4bHwDq8R4k3qa62lYFrxFn/xGJ/xXQoULaHxHu/xYnrY+xOdD0EVJG8L02muI0+is2ABL2Elj8BCjCBqyfULJs/yhuDySBIJMh9abXIJKd/ua43zrzB5AkKSOJcIG6MIWUP0rHDzmWD0B4D0doYIS58I8tEklBD027ryxVAoTUIBb9dFI0BHwpEeMgIBgxIC6SEARrKPRgkMUI8JYC8IYu9pZZ8eZp/2a9/2bz8IgTQflcD18D70xVD/NyhSHNF2HAyDLX8SKINyIp5nVLMT9zaPEU4PmC6h+HhCHEvZLZCvH5JvkocwSvYy+NVe8Ib/9agTLkH0+dbySwqlKoilVJbvC3NP960PkiXT+GV3KrJvKbR/CKAC85NA+NHq9cTQmBSgKv3Y+9D/+QAQWCYVK7ffC7lvCczv/K/v+z+3MdSfT48CkECf+oSq/MMgLW3VTzknVsqymNlSNQzjVX8/CHh0R8KQ/YOPHHgECAIAAxMJIxADEBEPAwACAwIWE42OAwMhAJmZIxoDBwICI5qjpKWaAgGmqqusra6vsLGys7S1tre4tAGppgGCucC3CQeWE7+PAxQUkxCd/wAkxBOTm5YkpZbYwdqxqL7Bw8XHlsrMztCE0wAj1aQJ2JYJt6jb9PX29/j5+qW7qt77AIFZGMAhoMFTu34dbDWwYL55CyNKnEjxYL9eCitqzIQo3kZ73TJ+7KgPoqkPLURI+MiypUuLvPiJfEmz5quQNkvGvIbNAY8KHXIKHUpUEwIE/j6BWsq0qdOnUKNKnUq1qtWrWLNqdXpAgQKlW8OKHdu0666zaN+9a4ABRdG3cIUGUIC2rt27ePOi9aq3r9++fP8KFhx4sGG9hQ8rrpt4seO5dPOqxUZ3ZdzLmDdejLiZ806DnWFODC161dq2mVOrHv0ZdGvXEkkHlA2Qdv/t15p8Al3Nu/ds3PtsBweeT3hx4scpGvfNvPm95c+RJ/fMurp159izR79Ovbv3hdC3ax9PPlf4eufRS7eXflt7be/hry9Pv36moxPx50caUX9//v9R5J99BBZo4IEIJqjgggw26OCDEEYo4YQUVrhgBhUEUEEGEmEYXy0IWAZAByIEIAKH+YSoiYcn6kOiiShmIgECQeEjQYkbZuJhjvncqGGMHs5n4ZD5NDCAAgM0EJEEHxzpAEASBHCkJkhaouQ9UU4JQAZGIvlBjPZUmaQmTA4gJC3vKJBJl2Pmk6aMTSrwJJF0RoTCAC0A0MIAbh3kwAAi7lOlmpmgkEEGfwL/SM+g942JpKL1GIroAPwZaWY+FYxoCQB35rlnn/dk2sGmAPwZaJ2o1naplGfmIsEADvyZJ0AIaDnKnzXaUyuhXCbpU0C4AhDABxhcmmKxqbAqrLH4IIAsAK/Gimeq1OqjrLIG1doAAkZmus+upIgwAAYpapkBDx/82QCY94hL7qsoYItPBUiSey2zodYLgLbcDuBttQBv4y4AxYpw0KtqylsuoZkUy4M+4AIgbip7tjqLw5lI+Y7Fszw6cMEAPYrwshwHbHIpozqAQLB+8mkkpPbcmCQCHO7pwC4wByPzthjO3G0+NuPcwVE8DMBDrvRwG0CxA3SQ8spNN9vA0pYE//UnCi+frDUuFfzpwL8GSWDkB2DjIyalg2x8z9lIYdDkzfqoFZPC9HRgqQN9dg1r2XXf3afYA5C99eCEF2744YgnrvjijDfu+OOQRy755JQHPLRlGQwoCwYMV+755wlK+UEmRVMCi5ZIgq766vZpvGE20PKgAAYcIhAACrK7VQGsAXSAJAottLBSBpzTxfrxyGMmpQMNiPBnIx18MLX0y35QZQfFWi8BkszDWuoHS8+Z/Pjk1ySluB+I24i4bhWbZdtoo06JkQB88AEPvZev//6aUWpkBpuSElIEKMBlIUV+mUidBFrwpw8gjX8QjGBxKNWBlWzqVS1Y2egKWEBY0YIodQBInQIqgAAknUqCKEyhedCWCVLprQEr4SDaNLY9SqRuT3tToQ53yMMe+vCHQAyiEIdIxCIa8YhITKISl8jEJjrxiVCMohSnSMUqWvGKWMyiFrfIxS568YtgDKMYx0jGMprxjGhMoxrXyMY2uvGNcIyjHOdIxzra8Y54zKMefRMIADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone mineral content in postmenopausal women during three years of treatment: the first two years with either placebo (red) or with estradiol cyclically combined with a small dose of norethisterone (blue); the women were then rerandomized to continued therapy or the other regimen in the third year. Estrogen therapy increased bone density when given as initial therapy (upper curve) and after two years of placebo. Replacement of estrogen with placebo led to a decline in bone density.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; 1:459.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13854=[""].join("\n");
var outline_f13_33_13854=null;
var title_f13_33_13855="Type III bipartite patella";
var content_f13_33_13855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Type III bipartite patella",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 466px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The smooth, regularly spaced separation between the main patella and unfused secondary ossification center is shown here (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Blount, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_33_13855=[""].join("\n");
var outline_f13_33_13855=null;
